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1 Introduction 
1.1 Non-small cell lung cancer (NSCLC) and treatment 
Lung carcinomas are one of the leading cancer diseases in Germany. It is the most frequent cause of 
death with a mortality rate of 25 % in men and the third-leading cause of death with a mortality rate 
of 14 % in women with cancer (1). A very poor prognosis is reflected in relatively low 5-year survival 
rates with 21 % in women and 16 % in men. Lung cancer is divided into three main types: An 
adenocarcinoma is diagnosed in one third of all cases, whereas one fourth accounts for squamous 
cell carcinoma and small cell lung carcinoma, respectively (2). Adenocarcinomas, squamous cell 
carcinomas and large cell carcinomas belong to the non-small cell lung carcinomas (NSCLC). This 
histological WHO classification is based on biological behaviour, prognosis and therapy options. The 
therapy depends on stage and time of diagnosis of the tumour. Curative resection is, if possible, the 
first-line treatment in stages I-IIIb after neo-adjuvant and following adjuvant chemotherapy. If the 
tumour is diagnosed rather late in stage IV with multiple metastases, which is the case in approx. 
40 % of NSCLC, only palliative chemotherapy is possible. The type of chemotherapy depends on the 
genetic status of the tumour cells. If the tumour shows an activating deletion mutation in Exon 19 or 
a L858R mutation in Exon 21 of the Epithelial Growth Factor Receptor (EGFR) (5-15 % of NSCLC 
patients in Europe and USA), patients benefit from a therapy with targeted drugs. Gefitinib and 
erlotinib, targeting the EGFR and inhibiting its tyrosine kinase activity show a remission rate of 70 % 
and a disease control rate of 90 % with a significantly better progression-free survival compared to 
standard chemotherapy, which is a platinum-based treatment in combination with radiation or e.g. 
taxans, gemcitabine, vinorelbin or pemetrexed. Using the standard therapy, remission rates of 15 to 
30 % and a mean progression-free survival of 3 to 5 months can be achieved (3). 
 
1.2 Cisplatin 
 
Figure 1 Molecular structure of cisplatin (4). 
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Cisplatin (cis-Diamminedichloroplatinum(II)) is one of three widely used platinum-containing 
chemotherapeutic agents used to treat solid tumours. Its chemical structure is shown in Figure 1. It 
was first synthetized in 1845 by Michele Peyrone (5). The cytotoxic effect of platinum was discovered 
by chance by Barnett Rosenberg in 1965 (6–8). Cisplatin is an uncharged, cis-configured, square-
planar platinum(II) complex, which has to be administered intravenously. At first it was approved in 
1978 by the FDA to treat testicular and bladder cancer. In addition, it is used today against other 
solid neoplasms like bladder, ovarian, lung and head and neck cancer. Many patients initially 
experience a therapeutic response and disease stabilisation. During further treatment, nearly every 
tumour develops a chemoresistance against cisplatin. This drawback is accompanied by severe 
adverse effects like nephrotoxicity, neurotoxicity and ototoxicity. Reduction of toxicity was the 
rationale behind the development of several cisplatin analogues described elsewhere (9–12). 
Because of the high potency and the lack of alternatives, cisplatin is still the backbone of many 
chemotherapeutic combination treatments in lung cancer (13). 
1.2.1 Mode of action 
Cisplatin elicits its cytotoxic effects through binding to DNA. This leads either to successful repair of 
DNA damage by several mechanisms or the irreversible activation of programmed cell death. Prior to 
DNA binding, cisplatin has to be activated by exchanging one or both chloride ligands for water. The 
aquation takes place in the cytosol resulting in a highly active diaquacomplex. Due to several 
nucleophilic binding and detoxification partners like glutathione, metallothionine and different 
proteins abundantly present in the cytosol, less than 10 % of cisplatin entering the cell eventually 
reaches the nucleus (14). Here, cisplatin reacts with different functional groups of the DNA, whereas 
the interaction with N7-sites of purine bases is predominant leading to bifunctional 1,2-intrastrand 
ApG (adenine-phosphate-guanine) or GpG (guanine-phosphate-guanine) crosslinks occurring in 
80 to 95 % of all lesions (15). The less abundant crosslinks are 1,3-intrastrand GpG crosslinks (5-6 %), 
interstrand GpG crosslinks (2-5 %) and monofunctional links with e.g. proteins (2-3 %) (14) (Figure 2). 
These lesions lead to activation of several DNA damage response pathways including repair 
mechanisms and apoptosis induction. 
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Figure 2 Cisplatin-DNA adducts (A: adenosine, G: guanosine, N: any nucleoside) (16). 
 
1.3 Repair mechanisms and apoptosis induction 
1.3.1 Cell response to DNA damage 
DNA damage recognition involves over 20 candidate proteins, which bind to the damaged DNA site 
leading either to DNA repair and cell survival or to apoptosis (15). First of all, the mismatch repair 
(MMR) system has to be mentioned, which is a highly conserved, strand-specific repair mechanism. 
After replication, Mut proteins recognise unmatched or mismatched DNA base pairs and initiate their 
excision. DNA base pairs are then resynthesized by DNA polymerases. The cisplatin-DNA adducts 
interfere with MMR proteins and hinder them to repair these DNA lesions completely (futile repair). 
This instability in the mechanism leads to apoptosis, initiated by MMR (17). Lesions caused by 
cisplatin are apparently not repaired by the MMR, but loss of this system contributes to 
chemoresistance (18), because cells can survive in spite of DNA damage. The second repair 
mechanism of DNA is the nucleotide excision repair (NER). DNA lesions altering the helical structure 
(e.g. cisplatin binding) and interfering with replication and translation are recognised by several 
proteins of the xeroderma pigmentosum group, like XPC. After marking the lesion and recruiting 
other proteins, like the excision repair cross-complementation group 1 (ERCC1), the area is unwound 
and excised. Again DNA polymerases fill up the resulting gap (19). Cisplatin-DNA adducts are mostly 
repaired by this mechanism, which is enhanced in platinum-resistant cells (18, 20). Other repair 
mechanisms like the base excision repair (BER) are of minor importance in cisplatin-DNA adduct 
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excision (18). Another mechanism to deal with DNA-damaging agents is the replicative bypass. Here 
some DNA polymerases have the ability to synthesize ignoring the damaged site. Cells can proceed 
the cell cycle to G2 phase and repair the damaged site before entering mitosis. Enhanced replicative 
bypass can be seen in many chemoresistant cell lines (18).  
1.3.2 Cellular stress affecting p53 
P53 is the most important tumour suppressor protein and centrally involved in cellular stress 
response. It influences cell cycle, apoptosis and DNA repair depending on its activation at different 
amino acid sites. P53 is mutated in more than 50 % of lung cancers. With a mutation frequency of 
42 %, it is one of the most frequently mutated genes leading to loss of function and unregulated 
cancer cell growth (21). Structurally, p53 consists of 393 amino acids and can be divided into several 
functional domains. The N-terminal transactivation domain and the proline-rich region are binding 
sites for several interacting proteins of the transcription machinery, like transcriptional co-activators 
p300 or CREB-binding proteins (CBP) and the major regulator Murine Double Minute 2 (MDM2). 
Proteins may compete for similar binding sites, making the p53 activation dependent of their 
concentration and binding affinity. This process is very complex, as the activation involves multiple 
phosphorylation sites at the N-terminus of p53. The functional domain of DNA binding is located in 
the centre of the protein, which is bound by a flexible linker to the C-terminal tetramerisation 
domain, making p53 bind to DNA as a tetramer. The rest of the C-terminus seems to be intrinsically 
disordered, but may undergo ordering after binding to specific proteins. Most of posttranslational 
modifications, like acetylation, ubiquitination, phosphorylation, sumoylation, methylation and 
neddylation seem to take place here and regulate p53 function, next to export or binding signals (22). 
1.3.3 Modifications of p53 in stress response 
P53 is consecutively expressed in a cell and kept on low protein levels by continuous degradation. 
Following cell stress, modifications of p53 especially at Ser-, Thr- and Lys-residues take place, leading 
to stabilisation of p53 and its accumulation in the nucleus. Different stress stimuli lead to different 
activation profiles of p53 and consequently to different functions. Phosphorylation and acetylation in 
response to DNA damage is still not fully understood. Several protein kinases like Chk2, Cdk-activated 
kinases CAK, the PI3K members Atm, ATR and DNA-PK phosphorylate p53 at serines and threonines 
in the N-terminal and C-terminal domains and strongly contribute to its activation (23) (Figure 3). 
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Figure 3 Map and post-translational modifications of human p53. Structure of p53: TAD, 
transactivation domain; PRD, proline-rich domain; DBD, DNA-binding domain; L, linker; 4DE, 
tetramerisation domain; CTD, C-terminal domain. Specific residues are modified as shown, with 
phosphorylation (P) in yellow, acetylation (A) in green, ubiquitylation (Ub) in purple, neddylation (N) 
in pink, methylation (M) in blue and sumoylation (SU) in brown. Proteins responsible for these 
modifications are shown in matching colours: AMPK, adenosine monophosphate-activated protein 
kinase; Atm, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related protein; 
AurK, Aurora kinase A; CAK, CDK-activating kinase; CDK, cyclin-dependent kinase; CHK, checkpoint 
kinase; CK, casein kinase; CSNK, cop-9 signalosome associated kinase complex; DNAPK, DNA-
dependent protein kinase; ERK, extracellular signal-regulated kinase; GSK3beta, glycogen synthase 
kinase 3beta; HIPK2, homeodomain-interacting protein kinase 2; JNK, c-Jun NH2-terminal kinase; 
MAPKAPK2, mitogen-activated protein kinase-activated protein kinase 2; p38, p38 kinase; PCAF, 
p300/CBP associated factor; PKC, protein kinase C; PKR, double stranded RNA-activated kinase; PLK3, 
pol-like kinase 3; RSK2, ribosomal S6 kinase 2; SET9, SET9 methyltransferase; SMYD2, SET/MYND 
domain-containing methyltransferase 2; SUMO, small ubiquitin-like modifier 1; TAF1, TATA-binding 
protein-associated factor 1; VRK1, vaccinia-related kinase 1 (24). 
 
1.4 Platinum resistance 
Typically, drug resistance is not restricted to a single mechanism but is the result of an accumulation 
of several mechanisms. Galuzzi et al. (13) classified these into four categories:  
• Pre-target resistance, preventing the binding of cisplatin to its target by reduced cellular 
accumulation or binding to cytoplasmic structures;  
• On-target resistance, by tolerating or repairing cisplatin-DNA adducts;  
• Post-target resistance, by several alterations or defects in signalling pathways responding to 
DNA damage; and  
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• Off-target resistance, by mechanisms, which are not directly related to cisplatin binding but 
altered upon the development of resistant phenotypes (Figure 4). 
 
Figure 4 Different mechanisms of cisplatin resistance (25). 
 
1.4.1 Pre-target resistance 
Pre-target resistance paraphrases every detoxification mechanism that targets cisplatin before 
binding to the nuclear target DNA. These mechanisms can on one hand reduce the cytoplasmic pool 
of cisplatin, through decreased influx or increased efflux or on the other hand lead to sequestration 
of activated cisplatin. Beside passive diffusion, it is well believed that cisplatin also enters the cell via 
active transport. Major influx transporters are copper transporters, especially CTR1, whereas major 
efflux transporters are ATP7B and MRP2. Alterations in their expression profile, subcellular 
localisation or functionality are associated with different cisplatin-resistant cancer models. 
Sequestration takes places, when aquated platinum species bind to nucleophilic substances, like 
glutathione, methionine, metallothioneins and other cysteine-rich proteins, acting as scavengers and 
reducing the level of active cisplatin in cancer cells (13). 
1.4.2 On-target resistance 
On-target resistance includes resistant mechanisms directly connected to cisplatin’s mode of action, 
the binding to nuclear DNA. Here resistant cells show alterations in different repair mechanisms, like 
increased proficiency in nuclear excision repair (NER), defects in the mismatch repair (MMR), 
increased activity of translesion synthesis (replicative bypass), increased homologous recombination 
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and binding of cisplatin to cytoplasmic components that are involved in extranuclear cytotoxicity of 
cisplatin. In the latter case it is still not clear, whether these mechanisms belong to on-target or post-
target resistance (25).  
As mentioned above, most of cisplatin-DNA adducts are removed by the NER system. Consequently, 
a higher activity of this repair mechanism can lead to chemoresistance against cisplatin, as shown in 
several preclinical cancer models (13), especially in NSCLC (26). Reduced expression of XPC and 
ERCC1, two central proteins in DNA damage recognition and excision of DNA lesions correlates with 
survival or response to cisplatin-based therapies (13). It is not sure, if increased activity of ERCC1 
corresponds with higher activity of NER in patients and if overexpression of ERCC1 enhances cisplatin 
resistance. Low expression of ERCC1 resulted in higher response to platinum-based chemotherapy 
and higher median survival. So this protein could be a future biomarker for elucidating cisplatin 
sensitivity (27).  
Recognition of DNA lesions by cisplatin is often done by the MMR system. MMR-related proteins, like 
MSH2 and MLH1 try to repair mismatch due to cisplatin-DNA adducts and induce a proapoptotic 
signal when failing to repair the damage (28). Mutations in these proteins or reduced expression can 
often be found in cisplatin-resistant cells. Defects in MLH1 and MSH6, other proteins of the MMR-
system lead to higher activity of the translesion synthesis (29), which is another mechanism of on-
target resistance. Here DNA replication is not stopped by a cisplatin-induced lesion, but proceeds 
until the arrest is induced in later cell cycle phases to start DNA repair. Several specific DNA 
polymerases show high activity, whereas the up-regulation of e.g. DNA polymerase POLH correlates 
with shorter survival in NSCLC patients (30). Defects in POLH or REV3, another polymerase, sensitise 
cells to cisplatin (31).  
The third mechanism of on-target resistance is homologous recombination, which usually tries to 
repair cisplatin-induced double-strand breaks in the S phase of the cell cycle. Here two proteins, 
BRCA1 and 2, often mutated in different cancer types, seem to play a major role in chemoresistance. 
BRCA1/2-deficient cancer cells show a higher sensitivity to cisplatin. Especially the development of 
resistance in those cells seems interesting, because some cancer cells try to compensate the 
BRCA1/2 deficiency by secondary mutations leading to cisplatin resistance (32).  
Last but not least, several extra-nuclear binding partners have been identified, like mitochondrial 
DNA, the mitochondrial anion channel, VDAC1 and cytosolic components, like HSP90 or myosin IIa, 
GRP78 or PDIA1/3. In mitochondria, it was shown that cisplatin leads to changes in the respiratory 
chain, which could be one possible extra-nuclear effect. For this reason, it remains unclear, whether 
these interactions lead to a cytotoxic effect and should be classified as on-target resistance 
mechanisms (25). 
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1.4.3 Post-target resistance 
Post-target resistance addresses all mechanisms recruited after binding of cisplatin to DNA being 
involved in the complex network of signalling cascades activated after DNA damage recognition. 
These changes in signalling lead to alterations in cell senescence or cell death signals and are 
involved in chemoresistance to different extents. The most prominent alteration in signalling is the 
inactivation of p53, which occurs in several cancer entities (33). The presence of p53-mediated 
apoptosis signalling is crucial for anticancer therapy, as it correlates directly with response to 
treatment (34). Besides this role in development of chemoresistance, the loss of p53-gene regulation 
is involved in the cancerogenesis process. Mutations of p53 occur in almost half of human cancers, 
leading to loss of functions or to overactivation in context of cell cycle control, apoptosis signalling, 
stress-independent p21 activation, angiogenesis, cell growth and proliferation (35).  
The second important signalling pathway may be pro-apoptotic signal transduction mediated by the 
mitogen-activated protein kinase (MAPK) family members, including extracellular related kinases 
(ERK1/2), mitogen-activated protein kinases p38 and c-Jun N-terminal kinases (JNK). All family 
members of the MAPK have a plenitude of regulatory functions in human cells. Among others, these 
kinase pathways lead to activation of p53 and apoptosis signalling. The role of these kinases in 
cisplatin resistance is still not clear. In some cells, activation of MAPK led to higher cisplatin 
sensitivity, whereas in other studies inhibition of MAPK led to higher sensitivity to cisplatin. Some 
researchers concluded, that chemoresistance against cisplatin is independent of MAPK (15). 
In addition to these complex networks, a lot of factors activated either by DNA damage or oxidative 
stress in mitochondria influence resistance against cisplatin. Among others, the functional status of 
BCL-2 family members (BCL-2-like proteins, BAX-like proteins), caspases, cell death receptors, which 
together execute the apoptotic cell death, PI3K signalling and Survivin pathways may contribute to 
cisplatin sensitivity or resistance (36). All these mechanisms, described elsewhere, contribute to 
post-target resistance. 
1.4.4 Off-target resistance 
Sensitivity of cancer cells can also be influenced by off-target mechanisms, which are not directly 
connected to cisplatin’s mode of action. These are alterations of survival signals or detoxification 
partners without direct activation by cisplatin. For example, overexpression of ERBB2, one of the 
EGFR family members, contributes to cisplatin resistance by sending a pro-survival signal via the 
antiapoptotic AKT1-signaling pathway. Consequence is a cell cycle arrest by up-regulation of the 
cyclin-dependent kinase inhibitor p21 enabling the cell to repair cisplatin-DNA lesions (37). Another 
resistance mechanism is the activation of DYRK1B, a nuclear protein kinase, which induces the 
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expression of antioxidant enzymes to cope with reactive oxygen species, which might be induced by 
cisplatin. The same idea may be also true for glutathione, which was already mentioned in the pre-
target section. GSH also binds reactive oxygen species and in consequence makes cells less sensitive 
to cell death signals (13). More general mechanisms contributing to cisplatin resistance are 
autophagy, including mechanisms of sequestration and lysosomal degradation (38) and the heat-
shock response, where cells are enabled to survive high temperatures and which is also activated in 
cell-stressing conditions (39). 
In conclusion, the comprehensive knowledge of cytoplasmic and nuclear actions of cisplatin and a 
resistance scheme with multifactorial activation of several mechanisms mentioned above, drives 
research to a systems pharmacology approach. This is supposed to lead to holistic models of the 
cell’s reaction to cisplatin for better understanding of the mechanisms underlying chemoresistance. 
 
1.5 Systems pharmacology 
Systems pharmacology was discussed extensively in a NIH white paper by the Quantitative and 
Systems Pharmacology (QSP) Workshop Group in 2011. Here the authors consider that systems 
pharmacology is an emerging discipline with different definitions in academia and industry: 
Academia generally defined it as an extension of classical pharmacology by systems biology: “systems 
pharmacology involves the application of systems biology approaches, combining large-scale 
experimental studies with model-based computational analyses, to study drug activities, targets, and 
effects” (40) or “…the quantitative analysis of the dynamic interactions between drug(s) and a 
biological system… (that) aims to understand the behaviour of the system as a whole, as opposed to 
the behaviour of its individual constituents” (41). On the other side, industry defines systems 
pharmacology as modelling of physiological processes by parameters of pharmacokinetics and 
pharmacodynamics in response to drug treatment. The resulting working definition, combining both 
sides of the story was developed by the working group as follows: "Quantitative and Systems 
Pharmacology is an emerging discipline focused on identifying and validating drug targets, 
understanding existing therapeutics and discovering new ones. The goal of QSP is to understand, in a 
precise, predictive manner, how drugs modulate cellular networks in space and time and how they 
impact human pathophysiology. QSP aims to develop formal mathematical and computational 
models that incorporate data at several temporal and spatial scales; these models will focus on 
interactions among multiple elements (biomolecules, cells, tissues etc.) as a means to understand 
and predict therapeutic and toxic effects of drugs" (42). This will involve classical well-known 
pharmacology, systems biological approaches (like protein networks in a whole cell system), large 
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scale studies (-omics technologies: genomics, transcriptomics, proteomics, metabolomics…) and 
model-based computational analysis of experimental data. 
The two basic approaches, systems biology and classical pharmacology are originally of horizontal 
integration in a system. This means that they refer to analysing the drug target, multiple receptors, 
signalling networks or metabolites at one time point, because molecules often react with multiple 
components of a system. Additionally, this involves the issue that even in precisely targeted 
therapies the consequences of a perturbation can be rather complex, involving different states of 
activity in time and space. Systems pharmacology adds the vertical integration to the complex. Here 
multiple spatial and temporal scales at different levels of biological complexity are analysed by multi-
omics approaches. This involves data on the reaction to a molecule in a defined system, like cells, 
tissues, organs, patients or populations. Vertical integration can be a bottom-up, top-down, or 
middle-out approach. For example, in relation to systems pharmacology and genome medicine, a 
bottom-up approach would be based on experimental and clinical analysis. By computational biology 
this is leading to the prediction and characterisation of new targets from biochemistry and cell 
physiology experiments and at the end the network analysis of the therapeutic intervention. A top-
down approach would come from a clinical diagnosis by genetic and genomic testing, computational 
processing of experimental data, leading to information for personalised medicine like personalised 
dosing or a combination therapy and reaching again the network analysis of the therapeutic 
intervention (Figure 5). Middle-out approaches would start at any level, wherever information is 
available and add data to both directions. 
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Figure 5   Horizontal and vertical integration in systems biology and pharmacology including 
also changes in physiological complexity and changes in time scales (from seconds 
and minutes to years and lifespans). The goal for QSP is to bring network-level 
understanding of drugs to the complex physiology of patient responses. The arrows 
denote trend lines (42). 
 
The selection of a system should be carefully considered in context of the issue (Figure 6). As the 
clinical analysis of a human could be too complex, the system analysed can be outlined on a lower 
level at the beginning. Even at molecular level an enzyme or a receptor can be analysed as a system 
reacting to different perturbations in different ways. A bottom-up approach then can also be the 
upscaling from a receptor or enzyme to a network level and further on to a tissue or organ level. 
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Figure 6 Possibilities of defining a system for systems pharmacological approaches, modified from 
(43). 
 
These experimental data should in the end be condensed in a multi-scale temporal and spatial 
model, to reflect an integrated picture of therapeutic and toxic effects of drugs. The modells could 
lead to new hypothese, which should be proofed experimentally. The final step is to link the 
mechanistic models of protein or gene networks to pharmacokinetics and pharmacodynamics in 
organs or patients. 
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2 Aim and objectives 
This project aimed at characterising the resistance mechanisms against cisplatin in non-small lung 
cancer cells using a systematic approach. Therefore, this piece of work was intended to be the first 
one in a series of systems pharmacology projects in our working group. 
A newly established cisplatin-resistant non-small cell lung cancer cell line (A549rCDDP2000) was 
characterised in comparison to its parental cell line (A549) regarding its reaction to cisplatin 
treatment including cytotoxicity tests, cellular platinum accumulation, cisplatin DNA-adduct 
formation, apoptosis induction and cell cycle status after treatment with equimolar and equitoxic 
cisplatin concentrations. As p53 is the crucial player in DNA-damage response and apoptosis-inducing 
pathways, this key protein and connected relevant up- and downstream players like pAtm, XPC, 
MDM2, GADD45a and p21 were analysed at the transcriptome and proteome level. The first step 
towards systems pharmacology was then done using a data-driven bottom-up approach. Here, the 
whole transcriptome served as a starting point to identify additional genes altered upon cisplatin 
exposure in sensitive and resistant cells using a whole genome array. After evaluation of these 
differentially expressed genes with RT-PCR, the next higher level of vertical integration within the 
cells was added: The key candidates were analysed additionally on protein level by Western blots to 
elucidate their contribution to the previously measured endpoints. Finally, the data were compiled in 
a signalling model to describe the differences in reaction to cisplatin treatment in both cell lines. 
  
Materials and methods 14 
3 Materials and methods 
3.1 Chemicals and reagents 
10x Blocking Agent Agilent Technologies, Santa Clara, USA 
25x Fragmentation Buffer Agilent Technologies, Santa Clara, USA 
2x GEx HI-RPM Hybridisation Buffer Agilent Technologies, Santa Clara, USA 
AccuMax PAA, Pasching, Österreich 
Acrylamide 30 % [m/V]  AppliChem GmbH, Darmstadt 
AffinityScript-RT Agilent Technologies, Santa Clara, USA 
AKT antibody (rabbit polyclonal IgG) Cell Signalling, Danvers, USA 
Ammonium persulfate (APS) AppliChem GmbH, Darmstadt 
Anti-rabbit poly-HRP Thermo Fisher Scientific, Oberhausen 
Argon 4.6 Air Product, Hattingen 
BCATM protein assay kit (Novagen®): 
Albumin standard ampoules (2 mg/mL bovine 
serum albumin) 
Reagent A (bicinchoninic acid) 
Reagent B (4 % cupric sulfate) 
Merck KGaA, Darmstadt 
BD Pharmingen™ FITC Annexin V Apoptosis 
Detection Kit 
BD Biosciences, San Jose, USA 
Binding buffer BD Biosciences, San Jose, USA 
Blocking buffer R&D Systems, Minneapolis, USA 
Boric acid  Fluka Chemie, Neu-Ulm 
Bovine serum albumin (BSA) Sigma-Aldrich, Steinheim 
Bromophenol blue AppliChem GmbH, Darmstadt 
CASYton, isotonic diluting solution Schärfe System, Reutlingen 
CCL2 antibody (rabbit polyclonal IgG) Aviva Systems Biology, San Diego, USA 
Cisplatin  Sigma-Aldrich, Steinheim 
Cisplatin-DNA adduct antibody Merck Millipore, Darmstadt 
Cobalt(II) sulfate heptahydrate Sigma-Aldrich, Steinheim 
Denaturation Cell Extraction Buffer Life Technologies, Carlsbad, USA 
Dithiothreitol (DTT) Applichem, Darmstadt 
dNTP Desoxynucleotide Mix Agilent Technologies, Santa Clara, USA 
DOK1 antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
DuoSet®IC R&D Systems, Minneapolis, USA 
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Human Phospho‐p53 (S15) Kit 
Electrophoresis buffer, 10 x [25 mM Tris base, 
192 mM glycin, 0.1 % sodium dodecyl sulfate] 
Bio-Rad Laboratories GmbH, München 
Ethanol 96-100 % [V/V] Merck KGaA, Darmstadt 
Ethylenediaminetetraacetic acid (EDTA), 
disodium salt dihydrate 
Sigma-Aldrich, Steinheim 
Fluoromount™ aqueous mounting medium Sigma-Aldrich, Steinheim 
Foetal calf serum (FCS) Sigma-Aldrich, Steinheim 
Formaldehyde 37 % [m/V] Riedel de Haën AG, Seelze 
GAPDH antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
Glucose monohydrate Sigma-Aldrich, Steinheim 
Glycerol 100 % [V/V] Applichem GmbH, Darmstadt 
Glycine Grüssing GmbH, Filsum 
Goat anti-mouse HRP antibody (polyclonal IgG) Santa Cruz Biotechnology, Inc., Heidelberg 
Goat anti-mouse poly-HRP antibody (polyclonal 
IgG) 
Thermo Fisher Scientific, Oberhausen 
Goat anti-rabbit antibody (polyclonal IgG)  SouthernBiotech, Birmingham, USA 
Goat anti-rabbit HRP antibody (polyclonal IgG) Santa Cruz Biotechnology, Inc., Heidelberg 
Goat anti-rabbit poly-HRP antibody (polyclonal 
IgG) 
Thermo Fisher Scientific, Oberhausen 
HRas antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
HRP substrate R&D Systems, Minneapolis, USA 
Hydrochloric acid [0.1 M and 1.0 M] Riedel de Haën AG, Seelze 
Hydrochloric acid 37 % [m/V] Merck KGaA, Darmstadt 
IMDM Medium PAN Biotech 
Isopropanol 100 % [V/V] Merck KGaA, Darmstadt 
JNK3 antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
Leupeptin hemisulfate Sigma-Aldrich GmbH, Steinheim 
L-Glutamin solution [200 mM] Sigma-Aldrich, Steinheim 
LightCycler 480® SYBR Green I Master Mix Roche Diagnostics, Rotkruez, Switzerland 
MDM2 antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
MDM2 antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
Methanol Merck KGaA, Darmstadt 
Mouse monoclonal p53 coating antibody Sigma-Aldrich, Steinheim 
My-Budget RNA Mini Kit Bio-Budget Technologies GmbH, Krefeld 
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Nitric acid 65 % [V/V], suprapur Merck KGaA, Darmstadt 
Non-fat dry milk powder Carl Roth GmbH & Co. KG, Karlsruhe 
Oligo dT-Promoter Primer Agilent Technologies, Santa Clara, USA 
p21 antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
p21 antibody (rabbit polyclonal IgG) Santa Cruz Biotechnology, Inc., Heidelberg 
p38 antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
p53-HRP antibody (mouse polyclonal IgG) Santa Cruz Biotechnology, Inc., Heidelberg 
pAKT antibody (rabbit polyclonal IgG) Cell Signalling, Danvers, USA 
pAtm antibody (mouse polyclonal IgG) Santa Cruz Biotechnology, Inc., Heidelberg 
Penicillin-streptomycin solution [10,000 
I.E./mL, 10 mg/mL] 
Sigma-Aldrich, Steinheim 
Pepstatin A Sigma-Aldrich, Steinheim 
PierceTM ECL Western blotting Substrate 
(luminol/enhancer, peroxide buffer) 
Thermo Fisher Scientific Inc., Rockford, USA 
PierceTM BCA Protein Assay Kit Life Technologies, Carlsbad, USA 
Potassium chloride Merck KGaA, Darmstadt 
Potassium dihydrophosphate  Fluka Chemie GmbH, Neu-Ulm 
PP2A antibody (rabbit polyclonal IgG) Bethyl Laboratories, Montgomery, USA 
Propidium iodide Sigma-Aldrich, Steinheim 
Protease Inhibitor Cocktail Sigma-Aldrich, Steinheim 
ProteinMarker V Peqlab GmbH, Erlangen 
PTK2B antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
PureLinkTM Rnase A Life Technologies, Carlsbad, USA 
QIAamp® DNA Mini Kit Quiagen, Hilden 
Ribonuclease A (RNAse) Sigma-Aldrich, Steinheim 
RNasin® Ribonuclease Inhibitors Agilent Technologies, Santa Clara, USA 
RNA Spike-In Kit Agilent Technologies, Santa Clara, USA 
RNeasy® Mini Kit Qiagen N.V., Hilden 
SCL9A9 antibody (rabbit polyclonal IgG) MBL, Nagoya, Japan 
Sodium azide Fluka Chemie, Neu-Ulm 
Sodium chloride Fluka Chemie, Neu-Ulm 
Sodium desoxycholate Sigma-Aldrich, Steinheim 
Sodium dodecyl sulfate (SDS) Applichem GmbH, Darmstadt 
Sodium hydrophosphate Applichem GmbH, Darmstadt 
Sodium hydroxide [0.1 M and 1.0 M] Riedel de Haën AG, Seelze 
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Sodium orthovanadate Applichem GmbH, Darmstadt 
Stop solution sulphuric acid R&D Systems, Minneapolis, USA 
T7 RNA Polymerase Agilent Technologies, Santa Clara, USA 
Tetramethylethylenediamine (TEMED) Applichem GmbH, Darmstadt 
Tris(hydroxymethyl)aminomethane (Tris base) Applichem GmbH, Darmstadt 
Tris(hydroxymethyl)aminomethane-
Hydrochloride (Tris-HCl) 
Applichem GmbH, Darmstadt 
Triton® X-100 Sigma-Aldrich, Steinheim 
Trypsin-EDTA solution [0.5 g porcine trypsin 
and 0.2 g EDTA in 100 ml] 
Sigma-Aldrich, Steinheim 
Tween®-20 Applichem GmbH, Darmstadt 
Ultrapure water Obtained by Purelab Plus™ system, Elga 
Labwater, Celle 
Whole Genome Array SurePrint G3 Human GE 
V2 8x60K Kit 
Agilent Technologies, Santa Clara, USA 
Wnt4 antibody (rabbit polyclonal IgG) GeneTex, Irvine, USA 
α-Actin antibody (mouse polyclonal IgG) Santa Cruz Biotechnology, Inc., Heidelberg 
β-Actin (C4) antibody (mouse polyclonal IgG) Santa Cruz Biotechnology, Inc., Heidelberg 
 
3.2 Buffers and solutions 
Phosphate-buffered saline (PBS) 
Sodium chloride  8.0 g 
Potassium chloride  0.2 g 
Sodium hydrophosphate dihydrate  1.44 g 
Potassium dihydrophosphate  0.24 g 
Ultrapure water  ad 1000.0 mL 
pH adjusted to 7.4 using sodium hydroxide or hydrochloric acid 
  
Cisplatin stock solution [5 mM] 
Cisplatin  1.5 mg 
Sodium chloride solution 0.9 %  1.0 mL 
  
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution [5 mg/mL] 
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MTT 50 mg 
PBS 5.0 mL 
  
DAPI stock solution [1 mg/mL]  
DAPI 1 mg 
Methanol 1000 µL 
  
DAPI working solution [5 μg/mL]  
DAPI stock solution 5 µL 
Ultrapure water ad 1000 µL 
 
3.2.1 SDS-PAGE and Western blot 
Cell lysis 
RIPA lysis buffer 
Tris-HCl (pH 7.6) 3.939 g 
NaCl 8.766 g 
Triton X-100 100 g 
Sodium desoxycholate  10 g  
SDS 1 g 
EDTA 0,292 g 
Ultrapure water ad 1000.0 mL 
  
Activated Na3VO4 solution*,** 10 µL 
Leupeptin solution [5 mg/mL in ultrapure water]** 2 µL 
Pepstatin A solution [2 mg/mL in DMSO]** 5 µL 
Protease inhibitor cocktail** 1 µL 
* Activation: Solution of sodium orthovanadate [10 mM] in ultrapure water, pH adjusted to 
10 and solution boiled yielding a clear solution. After cooling down, pH readjusted to 10. 
** added shortly before usage. 
  
SDS polyacrylamide gel electrophoresis 
Ammonium persulfate (APS) solution [10 %] 
APS 100 mg 
Ultrapure water ad 1000.0 µL  
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Dithiothreitol (DTT) solution [3.2 M] 
DTT 49.4 mg 
Ultrapure water ad 1000.0 µL 
  
Electrode buffer  
Glycin 
Tris-Base 
SDS 
Ultrapure water 
14.4 g 
3 g 
1 g 
Ad 1000.0 mL 
  
Loading buffer 
Stacking gel buffer 1.75 mL 
Glycerol 1.5 mL 
Sodium dodecyl sulfate solution (see 
below) 
5 mL 
Bromphenol blue solution* 1.25 mL 
* Saturated bromphenol blue solution in ultrapure water containing 0.1 % ethanol 
  
Sodium dodecyl sulfate (SDS) solution [10 %]  
SDS 1.0 g 
Ultrapure water ad 10.0 mL 
  
Stacking gel (5 %)  
Acrylamide 30 % 833 µL 
Stacking gel buffer (see below) 625 µL 
Ultrapure water 3445 µL 
SDS 10 % 50 µL 
TEMED* 5 µL 
APS 10 %* 20.8 µL 
* Added last for initiation of polymerisation 
  
Stacking gel buffer (pH 6.8)  
Tris base 12.11 g 
Ultrapure water ad 100.0 mL 
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pH adjusted to 6.8  
  
Separating gel (10%)  
Acrylamide 30 % 5000 µL 
Stacking gel buffer (see below) 5625 µL 
Ultrapure water 4093 µL 
SDS 10 % 150 µL 
TEMED* 27 µL 
APS 10 %* 105 µL 
* Added last for initiation of polymerisation 
  
Separating gel buffer (pH 8.8)  
Tris base 12.11 g 
Ultrapure water ad 100.0 mL 
pH adjusted to 8.8  
  
Western blot 
Tris-buffered saline (TBS) 
Sodium chloride  4 g 
Tris base  0.6 g 
Ultrapure water  ad 500.0 mL 
pH adjusted to 7.3 using hydrochloric acid 
  
Tris-buffered saline with Tween®-20 (TBS-T) solution 
Tween®-20 1.6 mL 
TBS ad 800.0 mL 
  
Blocking solution 
Non-fat dry milk powder 5 g 
TBS-T solution ad 100.0 mL 
  
Transfer buffer  
Glycine 14.4 g 
Tris base 3 g 
Methanol 200.0 mL 
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Ultrapure water ad 1000.0 mL 
pH adjusted to 8.2 to 8.4 using hydrochloric acid 
  
Antibody solutions for detection of proteins 
Primary antibody p38 solution (1:500)  
Sodium azide 10 mg 
BSA 500 mg 
p38 antibody 40 µL 
TBS-T solution 10.0 mL 
  
Primary antibody HRas solution (1:500)  
Sodium azide 10 mg 
BSA 500 mg 
HRas antibody 40 µL 
TBS-T solution 10.0 mL 
  
Primary antibody DOK1 solution (1:500)  
Sodium azide 10 mg 
BSA 500 mg 
DOK1 antibody 40 µL 
TBS-T solution 10.0 mL 
  
Primary antibody CCL2 solution (1:2000)  
Sodium azide 10 mg 
BSA 500 mg 
CCL2 antibody 5 µL 
TBS-T solution 10.0 mL 
  
Primary antibody PTK2B solution (1:333)  
Sodium azide 10 mg 
BSA 500 mg 
PTK2B antibody 30 µL 
TBS-T solution 10.0 mL 
  
Primary antibody MDM2 solution (1:1000)  
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Sodium azide 10 mg 
BSA 500 mg 
MDM2 antibody 10 µL 
TBS-T solution 10.0 mL 
  
Primary antibody JNK3 solution (1:333)  
Sodium azide 10 mg 
BSA 500 mg 
JNK3 antibody 30 µL 
TBS-T solution 10.0 mL 
  
Primary antibody SLC9A9 solution (1:333)  
Sodium azide 10 mg 
BSA 500 mg 
SLC9A9 antibody 30 µL 
TBS-T solution 10.0 mL 
  
Primary antibody p21 solution (1:333)  
Sodium azide 10 mg 
BSA 500 mg 
p21 antibody) 30 µL 
TBS-T solution 10.0 mL 
  
Primary antibody Wnt4 solution (1:1000)  
Sodium azide 10 mg 
BSA 500 mg 
Wnt4 antibody 10 µL 
TBS-T solution 10.0 mL 
  
Secondary anti-rabbit antibody solution (1:10000) 
Non-fat dry milk powder 0.5 g 
Anti-rabbit IgG horseradish peroxidase-
conjugated antibody 
1 µL 
TBS-T solution 10.0 mL 
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3.3 Equipment 
3.3.1 Instruments 
Accu-jet® pipetting controller  Brand GmbH & Co., Wertheim 
AllPrep DNA/RNA Mini Kit Qiagen N.V., Hilden 
Autosampler PSD 100 Varian, Darmstadt 
BD FACScaliburTM BD Biosciences, San Jose, USA 
Casy®1 cell counter, Modell TT Schärfe System, Reutlingen 
Centrifuge Mikro 200R Hettich GmbH & Co. KG, Tuttlingen 
Centrifuge Universal 32R Hettich GmbH & Co. KG, Tuttlingen 
DYNEX MRXe microplate reader Magellan Bioscience, Chelmsford, USA 
Finnpipette® (10-100 µL, 100 – 1000 µL) Thermo Electron GmbH, Dreieich 
Gel Doc ™ XR+ System Bio-Rad Laboratories GmbH, München 
Graphite Tube Atomisator GTA 100 Varian, Darmstadt 
Handystep® Brand GmbH & Co., Wertheim 
Hybridisation Oven Agilent Technologies, Santa Clara, USA 
Incubator Thermo Thermo Electron GmbH, Dreieich 
InoLab® pH level 2 pH Meter WTW GmbH, Weilheim 
Kern 770 analytical balance Kern & Sohn GmbH, Balingen-Frommern 
Kern EW analytical balance Kern & Sohn GmbH, Balingen-Frommern 
Laminar air flow work bench Heraeus Holding GmbH, Hanau 
LightCycler 480® Roche Diagnostics, Rotkreuz, Switzerland 
MT Classic AB135-S analytical balance Mettler-Toledo GmbH, Giessen 
Multiskan EX® microplate reader Thermo Electron GmbH, Dreieich 
NanoDropTM N-1000 Thermo Fisher Scientific, Oberhausen 
Nikon A1 Eclipse Ti confocal microscope Nikon, Kingston, UK 
Probes Master LC 480 Agilent Technologies, Santa Clara, USA 
PURELAB Plus system ELGA LabWater, Celle 
Shaker KS 15 control Edmund Bühler GmbH, Hechingen 
Slot Blot Manifold GE Healthcare, Solingen 
Spectrometer SpectrAA® Zeeman 220 Varian, Darmstadt 
SurePrint G3 Human GE V2 8x60K Agilent Technologies, Santa Clara, USA 
SureScan Microarray Scanner System Agilent Technologies, Santa Clara, USA 
Transferpette® S (0,5-100µL, 10-100 µL, 100-
1000 µL) 
Brand GmbH & Co., Wertheim 
Materials and methods 24 
Transferpette®-12 electronic (10-100 µL, 30-
300 µL) 
Brand GmbH & Co., Wertheim 
Ultrasonic bath Sonorex® Super RK 103 H Bandelin, Berlin 
3.3.2 Consumables 
Blotting paper (cellulose), 7 x 10 cm Sigma-Aldrich GmbH, Steinheim 
Casy® tubes  Schärfe System, Reutlingen 
Cell culture flasks 25, 75, 175 cm2  Sarstedt AG & Co., Nümbrecht 
Cell scraper  Sarstedt AG & Co., Nümbrecht 
Cryovials Sarstedt AG & Co., Nümbrecht 
Disposable syringe (10 mL) B. Braun Melsungen AG, Melsungen 
Glass Pipettes Labomedic GmbH, Bonn 
Graphite tubes  Varian (Agilent Technologies), Darmstadt 
Hybond nitrocellulose membranes GE Healthcare, Solingen 
Microscope slides Carl Roth GmbH & Co., Karlsruhe 
Pasteur pipettes Brand GmbH & Co., Wertheim 
Petri dishes Greiner Labortechnik, Frickenhausen 
Pipette tips Brand GmbH & Co., Wertheim 
Platinum hollow cathode lamps (UltrAA® 
lamps) 
Varian (Agilent Technologies), Darmstadt 
Reaction tubes (0.5, 1.5, 2 mL) Greiner Labortechnik, Frickenhausen 
Roti®-PVDF (Polyvinylidene fluoride) membrane Carl Roth GmbH & Co.KG, Karlsruhe 
Sample vials (2 mL, conical) Varian (Agilent Technologies), Darmstadt 
Tissue culture plates, 6 wells Sarstedt AG & Co., Nümbrecht 
Tissue culture plates, 96 wells Sarstedt AG & Co., Nümbrecht 
3.3.3 Software 
Ascent Software (for Multiskan EX®) Thermo Electron Inc., Dreieich 
AIDA Image Analyzer 4 Raytest, Straubenhardt 
BD CellQuestTM BD Biosciences, San Jose, USA 
Feature Extraction V 10 Agilent Technologies, Santa Clara, USA 
Flowing Software V 2.5 Turku Centre for Biotechnology, Finland 
GeneSpring GX 13.1 Agilent Technologies, Santa Clara, USA 
Graph Pad Prism® 6.00 GraphPad Software, San Diego, USA 
HTSanalyzeR Bioconductor, Roswell Park Cancer Institute, 
Buffalo, USA 
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Image LabTM 5.2.1 Bio-Rad Laboratories GmbH, München 
Microsoft® Excel 2010 Microsoft Corporation, Redmond, USA 
NIS-Elements software Nikon, Kingston, UK 
SpectrAA® 220, Version 2.20 Varian, Darmstadt 
 
3.4 Cell culture 
3.4.1 Cell lines 
In this study, the human adenocarcinoma derived non-small cell lung cancer cell line A549, sensitive 
to cisplatin (Figure 7) and its newly developed cisplatin-resistant sub-line A549rCDDP2000 were used. 
The sensitive cells were explanted from a 58-year old Caucasian male and cultivated in 1972 by Giard 
et al. (44). The A549 cell line was obtained from ATCC (Manassas, VA, USA) and its cisplatin-resistant 
sub-line A549rCDDP2000 was derived from the Resistant Cancer Cell Line (RCCL) collection 
(www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html). The sub-line had been established by adapting 
A549 cells in the presence of increasing concentrations of cisplatin until the target concentration of 
2000 ng/mL cisplatin as described previously (45).  
 
Figure 7 Image of A549 cells (46). 
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3.4.2 Cultivation and cell experiments 
A549 cells were grown in IMDM medium containing 4 mM L-glutamine, supplemented with 10 % 
foetal calf serum (FCS), 100 I.E./mL penicillin and 0.1 mg/mL streptomycin. The medium of the 
A549rCDDP2000 cells additionally contained 2000 ng/mL cisplatin. Cells were cultivated as monolayers 
in a humidified atmosphere at 37 °C and 5 % CO2. Cell growth, morphology and viability of cells were 
checked regularly by a light microscope. Cells were grown until a confluence of 80 % and either sub-
cultivated (approx. every third day) or used for an experiment. Backups of each cell line were 
suspended in FCS with 10 % DMSO and stored in liquid nitrogen. For each experiment, cells were 
counted and allowed to attach overnight, experienced 4 h of serum starvation and were 
subsequently treated with cisplatin for 24 h in IMDM medium without any supplements. The cisplatin 
concentrations used were cell line-dependent and based on the respective EC10 (concentrations, 
which produce 10 % of the maximum possible response). Both cell lines were treated with 11 µM 
cisplatin (EC10 of sensitive cell line). The resistant sub-line was also treated with 34 µM cisplatin (the 
respective EC10). In the following, equimolar treatment refers to treatment of the sensitive and 
resistant cell line with 11 µM cisplatin and equitoxic treatment refers to treatment of the sensitive 
cell line with 11 µM cisplatin and the resistant cell line with 34 µM cisplatin. 
3.4.3 Test for mycoplasma contamination 
Mycoplasma is a genus of small (0.22 to 2 µm), wall-less bacteria, which are able to grow on different 
substrates and cultivated cells. A contamination with mycoplasma can lead to genetic changes and 
death of cells. The A549 and A549rCDDP2000 cells were therefore routinely checked for an infection 
with mycoplasma. Detection was performed using the fluorescence dye DAPI (2-(4-amidinophenyl)-
1H-indole-6-carboxamidine dihydrochloride), which binds to cellular DNA and mycoplasma DNA. 
DAPI was detected by fluorescence microscopy after exciting with ultraviolet light through a blue 
filter. Cells were cultivated on microscope slides in a Petri dish for three days without medium 
change in IMDM without antibiotic supplements. After washing once with PBS, cells were fixed with 
methanol and subsequently incubated with 5 µg/mL DAPI working solution at room temperature for 
5 min. Afterwards, slides were washed twice with 2 mL methanol and Fluoromount™ aqueous 
mounting medium was used to fix cover slips on the slides. Analysis was performed using a Nikon A1 
Eclipse Ti confocal laser scanning microscope. A mycoplasma contamination would be visible as blue 
pointed shades around the cell nucleus. During the experimental period of this study, no 
contaminations were detected as shown in Figure 8.  
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3.5 Cytotoxicity assay (MTT) 
3.5.1 Principle 
The MTT assay was performed to determine the cytotoxicity of cisplatin in the cells. Cisplatin 
concentrations that resulted in 90 % cell viability relative to an untreated control (EC10) were 
determined. The underlying principle is the formation of insoluble violet formazan crystals from 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) through mitochondrial 
dehydrogenases. With increasing concentrations of the drug, the viability and with it the 
mitochondrial activity of the cells decrease, leading to reduced formation of the violet formazan 
product. Its concentration can be measured in an UV spectrometer, as the absorption is proportional 
to the amount of formazan formed. This analysis results in a sigmoidal concentration-response curve 
with the turning point giving the pEC50 value (concentration which produces 50 % of the maximum 
possible response). This assay was performed as presented elsewhere (47, 48). 
3.5.2 Procedure 
8000 cells per well were seeded in a 96-well microtiter plate in 80 µL IMDM and kept at 37 °C and 
5 % CO2 overnight. The outer wells of the microtiter plate were filled with PBS (Table 1). Four hours 
before treatment, medium was changed to 80 µL non-supplemented IMDM in accordance to other 
experiments. Cell treatment was performed by adding cisplatin dissolved in 20 µL 0.9 % NaCl in 
different concentrations, leading to the indicated end-concentrations in each well (Table 1). Each 
concentration was tested in triplicates and control samples were treated with 0.9 % NaCl. Following 
24 h of incubation, 20 µL of MTT solution [5 mg/mL dissolved in phosphate buffered saline] were 
added for 1 h at 37 °C and 5 % CO2. Then, the medium was removed, and formazan crystals were 
dissolved in 100 µL DMSO. Absorbance of the converted dye was measured at 595 nm with 
background subtraction at 690 nm using a Multiwell-Reader Multiskan EX®.   
a) b) 
Figure 8 Representative fluorescence image of a negative test for mycoplasma contamination in a) 
A549, passage 59 and b) A549rCDDP2000, passage 104. The DNA is indicated in blue. 
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Table 1 Scheme of 96-well plate with concentrations of cisplatin used for the MTT assay, PBS: 
phosphate buffered saline; CTR: control. 
Cisplatin concentration [µM] 
 1 2 3 4 5 6 7 8 9 10 11 12 
A PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
B PBS CTR 0.5 1 5 10 30 50 70 100 500 PBS 
C PBS CTR 0.5 1 5 10 30 50 70 100 500 PBS 
D PBS CTR 0.5 1 5 10 30 50 70 100 500 PBS 
E PBS CTR 0.5 1 5 10 30 50 70 100 500 PBS 
F PBS CTR 0.5 1 5 10 30 50 70 100 500 PBS 
G PBS CTR 0.5 1 5 10 30 50 70 100 500 PBS 
H PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
 
The resulting pEC50 values were estimated using the software GraphPad PrismTM. Concentration-
effect curves were calculated by non-linear regression (settings: no comparison, constraint: 
‘BOTTOM must be greater than 0.0’, no weighting, consider each replicate Y value as an individual 
point) based on a four-parameter logistic Hill equation (49). The resistance factor was calculated by 
dividing the EC50 of the resistant cell line by the EC50 of the respective sensitive cell line. 
 
3.6 Protein quantification 
3.6.1 Principle 
In the experiment measuring intracellular platinum accumulation, platinum had to be referred to 
cellular platinum content instead of cell count, as different growth characteristics of sensitive and 
resistant cells could not ensure an equal number of cells after attachment over night for treatment. 
Besides that, total cellular protein content had to be determined to load equal amount of proteins 
into the pockets of the SDS gel electrophoresis. Cellular protein concentration was determined using 
the bicinchoninic acid assay (BCA™ Protein Assay Kit) according to the manufacturer’s instructions 
(50). A validation with respect to calibration curve linearity, working range, precision, accuracy, lower 
limit of quantification has been reported previously in our group (4, 51). 
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Different amino acids in proteins reduce Cu2+ to Cu+ quantitatively, which can react with two 
molecules bicinchoninic acid to form a violet chelate complex (Figure 9). This complex can be 
analysed with an UV spectrometer. The absorption measured with an UV spectrometer at 562 nm is 
proportional to the concentration of the chelate complex and therefore proportional to the protein 
quantity. The quantification was done in a 96-well microtiter plate with calibration curve standards 
and quality control samples on each plate. Every sample was measured in triplicate. 
 
Figure 9 Chemical reaction underlying the protein quantification with the BCA assay (51). 
 
3.6.2 Standard solutions and quality control samples 
Six standard solutions for generating a calibration curve were measured on each 96-well plate in 
triplicates. Solutions were prepared dissolving BSA-containing protein standard (2 mg/mL) provided 
by the manufacturer in sterile ultrapure water according to Table 2. To assure the quality of the 
measurement, quality control samples in three different concentrations in the calibration range were 
measured in triplicates on each 96-well plate. Quality control samples were prepared by diluting BSA-
containing protein standard of a different batch according to Table 2. 
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Table 2 Standard solutions and quality control samples for protein quantification using the 
BCA assay. 
 
Volume BSA 
[µL] 
Volume ultrapure 
[µL] 
Protein concentration 
[µg/mL] 
Standard solution    
S1 50 1950 50 
S2 75 1925 75 
S3 100 1900 100 
S4 200 1800 200 
S5 300 1700 300 
S6 400 1600 400 
Quality control samples    
QC1 150 1850 150 
QC2 250 1750 250 
QC3 350 1650 350 
 
3.6.3 Sample preparation 
For cellular platinum accumulation experiments, 20 µL of cell sample were lysed with 10 µL of 
1 M NaOH in an ultrasonic bath for 30 min. After centrifugation, 10 µL of 1 M HCl were used for 
neutralisation and lysate was diluted with 40 µL of ultrapure water (dilution factor 4). From this 
dilution, proteins were quantified in triplicate in a 96-well plate. Standard solutions and quality 
control samples were treated in the same way than the cell samples, diluted as well with 10 µL of 
1 M NaOH and 10 µL of 1 M HCl, but subsequently not diluted with 40 µL of ultrapure water.  
To perform protein quantification for SDS gel electrophoresis, 20 µL of cell lysate were diluted with 
80 µL of ultrapure water (dilution factor 5). Afterwards, proteins were again quantified in triplicate in 
a 96-well plate. 25 µL of standard solutions and quality control samples were added without any 
further preparation.  
For both ways of preparation, a 50:1 mix of BCA working reagent A (BCA) and BCA working reagent B 
(CuSO4) was prepared and 200 µL were added to each well containing 25 µL of a cell sample. The 
plate was incubated 15 – 30 min at 60°C. Absorbance was subsequently recorded at 570 nm using a 
Multiwell-Reader Multiskan EX®. 
Microsoft® Excel 2010 was used to perform linear regression based on the mean of triplicates and to 
calculate protein concentration. Calibration curve was accepted when at least four of the standard 
solutions show a deviation of ≤ 15 % from the nominal value (20 % at lower limit of quantification) 
and two of the quality control samples show a deviation of ≤ 15 % of the nominal value. Correlation 
coefficient (r) had to be ≥ 0.99 (weight 1/x). 
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3.7 Cellular platinum accumulation 
Cellular platinum accumulation was measured to evaluate differences in platinum uptake in the cell 
lines, which may contribute to resistance development. 2.5 × 105 sensitive cells and 5 × 105 of the 
resistant sub-line per well were seeded in 6-well plates and left at 37 °C and 5 % CO2 overnight. After 
4 h of serum starvation and treatment with cisplatin for 24 h, cells were washed with ice-cold PBS, 
trypsinised and centrifuged for 4 min at 1500 x g in 2 mL Eppendorf tubes. Cells were reconstituted in 
1.0 mL PBS and 20 µL of the solution were taken aside for protein quantification. The cell pellet was 
washed again with PBS and stored at -20°C until platinum quantification. 
After lysing the cell pellet in 50 µL concentrated HNO3 at 80 °C for 1 h, measurement of the total 
platinum content was performed using flameless atomic absorption spectrometry. The method was 
described elsewhere (52) and used in a modified way, according to the validation performed in our 
group (53). Briefly, at the beginning of every measurement a calibration curve between 5 and 
50 ng platinum/mL was recorded. During measurement run, quality was assured by measuring 
different quality control samples with 10, 20 and 40 ng platinum/mL. The diluted sample was 
injected into a graphite tube with an autosampler. After vaporisation and atomisation, platinum 
absorption was measured at 265.9 nm and 2700 °C. Every sample was measured at least in duplicate 
but maximal four times depending on the precision of each measurement. The cellular platinum 
content was referred to the cellular protein quantity, which was determined using the BCA assay as 
described in section 3.6.  
Microsoft® Excel 2010 was used to perform linear regression based on the mean of replicates and to 
calculate platinum concentration which was referred to cellular protein content. Calibration curve of 
platinum measurement was accepted when standard solutions showed a deviation of ≤ 15 % from 
the nominal value (20 % at lower limit of quantification) and at least two of the quality control 
samples showed a deviation of ≤ 15 % of the nominal value.  
 
3.8 Cisplatin-DNA adducts 
Cisplatin-DNA adducts were measured by immunoblotting. After 4 h of serum starvation and 
treatment with different concentrations of cisplatin for 24 h, total DNA was isolated with the 
AllPrep® DNA/RNA Mini Kit. 1 µg of DNA was dissolved in Tris/EDTA (TE) buffer and denatured at 
95 °C for 10 min. Subsequently, the DNA was spotted on HybondTM nitrocellulose membranes with a 
slot blot manifold by a vacuum of 35 kPa. After denaturation with 0.4 M NaOH for 45 min on a 
drenched filter paper the binding sites at the membranes were blocked with 5 % (w/v) non-fat dry 
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milk in Tris-buffered saline with 0.1 % (v/v) Tween-20 (≙ TBS-T) overnight at 4 °C. Subsequently, the 
membranes were incubated with the antibody against cisplatin-DNA adducts, diluted 1:1000 in TBS-T 
with 5 % (w/v) non-fat dry milk powder, for 2 h at room temperature to detect 1,2-d(GG) DNA 
intrastrand cross links. The membranes were washed three times with TBS-T followed by incubation 
with the secondary HRP-coupled antibody (1:1000). Antibody complexes were detected using the 
enhanced chemiluminescence (ECL) reagent and densitometric analysis was carried out using the 
AIDATM 4 software. 
 
3.9 Cell cycle analysis with flow cytometry 
3.9.1 Principle 
Flow cytometry is a laser-based technology used in cell sorting or cell counting. Small particles like 
cells or nuclei are separated in a fluid stream and pass a laser beam, which is diffracted and 
subsequently detected as side-scattered light (SSC) and forward-scattered light (FSC). SSC provides 
information about the granularity of the cells and FSC about the size of cells. Additionally, specific cell 
components tagged with a fluorescence dye can be detected by emitting fluorescence after 
excitation with the laser. For cell cycle analysis, cellular DNA content is analysed, as it differs in 
different cell cycle phases. Cellular DNA is therefore tagged with the intercalating fluorescent dye 
propidium iodide (PI). PI binds to DNA without any sequence preference and in a stoichiometric 
manner, resulting in a proportional ratio of DNA to fluorescence.  
3.9.2 Cell cycle phases 
The cell cycle can be divided into two major phases: the mitosis (M phase), where one cell divides 
into two genetically similar daughter cells and the interphase between mitosis. The interphase again 
is divided into three phases: the G1 phase, where the cell grows, produces RNA and proteins and 
prepares for DNA synthesis; the S phase, where DNA is replicated and the G2 phase, where the cell 
grows further and prepares itself for mitosis. Additionally, there is a phase called G0, where cells rest 
and do not proceed for dividing. The DNA content of every phase differs during cell cycle. After DNA 
replication in the G2/M phase, the DNA content is twice as high as before replication in the G0/G1 
phase. The DNA content in the S phase should be somehow in between the other phases, because 
the cells start with replication here.  
3.9.3 Procedure 
5 × 105 sensitive cells and 1 × 106 cells of the resistant sub-line were seeded into 25 cm² flasks and 
kept at 37 °C and 5 % CO2 overnight. After 4 h of serum starvation and cisplatin treatment for 24 h, 
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the supernatant was collected and cells were washed once with PBS, harvested with AccuMax and 
transferred to the consolidated supernatants. Subsequently, cells were centrifuged 5 min at 200 x g, 
the supernatant was discarded and cells were fixed with 79 % ethanol for 24 h at 4 °C. After fixation, 
cells were centrifuged for 5 min at 1400 x g, washed with PBS and incubated with 100 µg/ml RNase A 
for 30 min at room temperature. After staining with 5 µL propidium iodide (0.1 mg/mL in PBS) 
samples were analysed using the flow cytometer FACSCaliburTM and evaluated with BD CellQuestTM. 
 
3.10 Apoptosis assay 
3.10.1 Principle 
Cells that undergo apoptosis show several morphologic changes such as loss of plasma membrane 
symmetry and attachment. Loss of plasma membrane symmetry is reflected in the translocation of 
phospholipid phosphatidylserine (PS) from the inner to the outer side of the membrane. Outside the 
plasma membrane PS can be specifically bound by Annexin V, which is conjugated to the detectable 
fluorochrome fluorescein isothiocyanate (FITC). Combined with the vital dye propidium iodide (PI), 
which is only able to enter the cell at later apoptotic/necrotic stages where the cell membrane is 
permeable, this assay distinguishes between early apoptotic cells (Annexin V-FITC positive, PI 
negative) and late apoptotic/necrotic cells (Annexin V-FITC positive, PI positive). 
3.10.2 Procedure 
The apoptosis assay was performed using the BD Pharmingen™ FITC Annexin V Apoptosis Detection 
Kit according to the manufacturer’s instruction. 2.5 × 105 sensitive cells and 5 × 105 cells of the 
resistant sub-line per well were seeded into 6-well plates and kept at 37 °C and 5 % CO2 overnight. 
Additionally to the cisplatin treatment with 11 µM and 34 µM, cells were treated with 0.4 µM and 0.8 
µM of actinomycin D as a positive control. These concentrations were defined by a pre-evaluation 
experiment. After 4 h of serum starvation and 24 h treatment, trypsinised cells were added to 
previously collected supernatant centrifuged for 4 min at 1500 × g and washed twice with PBS. 
Supernatant was exchanged against 500 µL binding buffer (included in BD Pharmingen™ FITC 
Annexin V Apoptosis Detection Kit). 5 µL PI and 5 µL Annexin V-FITC were added to 100 µL of the 
resulting solution. After 15 min of incubation on ice, the solution was diluted with 300 µL binding 
buffer and analysis was performed using the flow cytometer FACSCaliburTM and evaluated using the 
Flowing Software V 2.5.  
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3.11 Whole genome array 
Total ribonucleic acid RNA was isolated from both treated and untreated cell lines using the my-
Budget RNA Mini Kit or the RNeasy® Mini Kit through different spin columns according to the 
manufacturer’s instructions. Isolated RNA was stored at -80°C until analysis was performed. 
 
Figure 10 Flow chart of sample preparation for the whole genome array according to the manual of 
the SurePrint G3 Human GE V2 8x60K Kit (54). 
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The transcriptome was then analysed using the Whole Genome Array SurePrint G3 Human GE V2 
8x60K Kit according to the manufacturer’s instruction (Figure 10). Total RNA was transcribed to cDNA 
using AffinityScript-RT, Oligo dT-Promoter Primer and T7 RNA Polymerase and labelled using the RNA 
Spike-In Kit (positive controls) including Cyanin 3-CTP (Cy3) dye. After purifying the labelled/amplified 
cRNA using the RNeasy® Mini Kit, cRNA was quantified spectrophotometrically (UV/VIS) using a 
NanoDropTM ND-1000. 40 µL of equivalent amounts of Cy3-labelled cRNA in 10x Blocking Agent and 
25x Fragmentation Buffer, diluted with 2x GEx HI-RPM Hybridisation Buffer (all included in the 
SurePrint G3 Human GE V2 8x60K Kit) were loaded on the gaskets of the microarray slide and kept at 
65 °C for 17 h with 10 rpm of agitation. After washing twice with different washing buffers (included 
in the SurePrint G3 Human GE V2 8x60K Kit), the microarray was read out with the SureScan 
Microarray Scanner System to measure immunofluorescence intensity. The data were analysed by 
the Feature Extraction software and the multiples of differentially expressed genes were calculated. 
 
3.12 Gene expression analysis  
3.12.1 Principle 
Gene expression analysis was performed using real-time quantitative PCR: Firstly, the cDNA needs to 
be denaturised at 95 °C and split into single strands (denaturation phase), secondly, the primers bind 
to DNA at a primer-specific annealing temperature (hybridisation phase), thirdly, DNA polymerases 
need to elongate the missing DNA strand at a polymerase-specific temperature (68 – 72 °C), starting 
at the 3’-end of the primer which serves as a starting point of the complementary strand 
(polymerisation phase). Theses phases are executed in recurring cycles.  
Real-time qPCR adds a detection phase to each cycle of the PCR, where quantification of the 
amplified product is performed. Depending on the method, this takes place at the end of the 
hybridisation phase (fluorescent reporter probe method) or at the end of each cycle after 
polymerisation (SYBR Green method). 
3.12.2 Fluorescent reporter probe method 
The fluorescent reporter probe method relies on Förster resonance energy transfer (FRET). Two 
specific fluorophore oligonucleotides, one bound to a FRET donor and one bound to a FRET acceptor 
bind next to each other to the target cDNA. If bound, both fluorochromes are close enough, so that 
energy, created by a light source at defined wave length, can be absorbed by the FRET donor and 
transferred to the FRET acceptor. The FRET acceptor then emits the energy as light of higher wave 
length. The intensity of the emitted light is proportional to the amplified target cDNA. 
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RNA was isolated using the RNeasy® Mini Kit and quantified with a NanoDropTM N-1000. 
Subsequently, cDNA synthesis was performed for 60 min at 42 °C. Reaction mixture was composed of 
2 µl water, 1.5 µl 10 x buffer, 1.1 µl MgCl2 (25 mM), 1.5 µl dithiothreitol (100 mM), 1.5 µl dNTP 
(2,5 mM), 0.6 µl RNasin® (20 units/µl), 0,3 µl oligo-dt-primer and murine leukaemia virus reverse 
transcriptase (50 units/µL) (55). RT-PCR was then performed with Probes Master LC 480 according to 
the manufacturer’s instructions. Hybridisation probes and primers were purchased from TIB 
MOLBIOL and are described in Table 3. PCR efficiency was evaluated by analysis of four different 
cDNA concentrations (1:10 to 1:10000) and results were corrected accordingly. 
 
Table 3 Description of hybridisation probes and primers for PCR analysis using the fluorescent 
reporter probe method. 
Gene p53 SIP 
Forward primer GCTGCTCAGATAGCGATGGTCT CGGTACCATTGGGCCAACTA 
Reverse primer GTACAGTCAGAGCCAACCTCAG GCTGAGAAACCAGTGCAAGTATCTA 
LC probe LC640-TCTGTCATCCAAATACTCCACACGC-PH CCACAAACATTTTATTCAGCCTCTGG-PH 
FL probe GCACCACCACACTATGTCGAAAAGT-FL TGGTTGGAGGAAGAACTGACTTCA-FL 
Annealing temp. [°C] 57 57 
Gene Actin GADD45A 
Forward primer AGCCTCGCCTTTGCCGA AAGCTGCTCAACGTCGACC 
Reverse primer CTGGTGCCTGGGGCG CGTCACCAGCACGCAGT 
LC probe LC640-CGACGACGAGCGCGGCGATATC-PH 
LC640-AGCCACATCTCTGTCGTCGTCCTCGT-
PH 
FL probe TTGCACATGCCGGAGCCGTTG--FL CTGGATCAGGGTGAAGTGGATCTGCA--FL 
Annealing temp. [°C] 61 58 
Gene XPC p21 
Forward primer CGATGGGGATGACCTCAGG GAGGCCGGGATGAGTTG 
Reverse primer TTTCTTCCTCTTCTTCATTGCTG GAGTGGTAGAAATCTGTCATGCTG 
LC probe LC640-TGTGCCTTCTTGAGGTCACTTGG-PH LC640-GTCTTGTACCCTTGTGCCTCGCTC-PH 
FL probe CATGGTAGCCCCTCTCTTCAGATG-FL GAGGAAGACCATGTGGACCTGTCAC-FL 
Annealing temp. [°C] 57 58 
Gene MDM2  
Forward primer CAGATGAATTATCTGGTGAACGA  
Reverse primer AAACTGAATCCTGATCCAACC  
LC probe LC640-TGTTGTGAAAGAAGCAGTAGCAGTGA-PH  
FL probe CTGGCTCTGTGTGTAATAAGGGAGAT-FL  
Annealing temp. [°C] 53  
LC Probe: FRET acceptor with LightCycler® red emitting light at 640 nm, FL Probe: FRET donor with 
3'-Fluroescein  
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3.12.3 SYBR Green method 
This method uses the fluorescence dye SYBR Green I (N',N'-dimethyl-N-[4-[(E)-(3-methyl-1,3-
benzothiazol-2-ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-1,3-diamine), which 
intercalates in double-stranded DNA or binds to the minor groove of DNA in a stoichiometric manner. 
The intensity of the fluorescence is again proportional to the amplified target DNA. At the end of the 
amplification cycles, a melting curve is recorded to validate the applied method and primers. The 
amplified product melts at one, for the fragment specific temperature, where the double strand is 
denaturised to two single strands. This leads to the release of SYBR Green I and a change in 
fluorescence intensity. 
Whole cellular RNA was isolated after treatment using the my-Budget RNAse Mini Kit and quantified 
with a NanodropTM N-1000. Subsequent cDNA synthesis was performed as described above in section 
3.11 (55). According to the manufacturer’s instructions, the following RT-PCR was performed with 
LightCycler® 480 SYBR Green I Master Mix. Primers were purchased from Life Technologies, USA and 
are described in Table 4. Quality of the PCR was proven by recording the melting curve of each DNA 
product. PCR efficiency was evaluated by analysis of four different cDNA concentrations (1:10 to 
1:10000) and results were accordingly corrected. 
Table 4 Description of primers for PCR analysis using the SYBR Green method. 
Gene 
Forward Primer 
Sequence (5' to 3') 
Reverse Primer 
Sequence (5' to 3') 
Annealing 
Temp. [°C] 
Product 
Length [b] 
P38 TGCCGCTGGAAAATGTCTCA GTTGTTCAGATCTGCCCCCA 60 357 
HRAS TGGACGAATACGACCCCACT CCAACGTGTAGAAGGCATCC 60 393 
DOK1 TCTACCTGAGAAGGACGGCA TCCAGGCACAGTCCAACATC 60 365 
CCL2 CGCCTCCAGCATGAAAGTCT TGTCTGGGGAAAGCTAGGGG 60 372 
PTK2B TTGCCATGGAGCAAGAGAGG GACCTTTTCAGCCTCCCACA 60 341 
MDM2 CCTAAGCCAGACGGGGACTA TCCACCCATAAAGCGCAACT 60 483 
JNK3 AAGCACCTCCATTCTGCTGG GGAAGGTGAGTCCCGCATAC 60 397 
SLC9A9 TCCCCTGGAACTTTCAGCAC GTTGTAGTCAGCGGAGGACC 60 418 
CDKN1A CCGTCTCAGTGTTGAGCCTT GCCAGTGTCTCCCTCCTAGA 60 388 
WNT4 TCGTGCCTGCGTTCGCT GTCAGAGCATCCTGACCACTG 60 459 
b = nucleotides 
 
3.12.4 Data analysis 
Results of the real-time qRT-PCR are presented as fold change relative to untreated control to display 
the effects of cisplatin. Additionally, the results are presented as absolute data, displaying also the 
expression levels of untreated controls. The quantitative endpoint for real-time PCR is the threshold 
cycle (Ct). The Ct is defined as the PCR cycle at which the fluorescent signal of the reporter dye 
crosses an arbitrarily placed threshold (56). There is an inverse correlation between Ct and the 
Materials and methods 38 
amount of amplicon: The earlier the threshold is crossed, the higher is the amount of the target gene 
in the sample. However, using a relative quantification, the data is referred to an internal reference 
gene (ΔCt = Ct (reference) – Ct (gene of interest)). Calculation is done by using the widely accepted comparative 
Ct method (56, 57). 
Fold change is calculated as follows by considering the efficiency (E) of the PCR reaction (Equation 1). 
Here the Ct value of the gene of interest is referred to the internal reference gene and the untreated 
control (ΔΔCt): 
 
Equation 1   𝐅𝐨𝐥𝐝 𝐜𝐡𝐚𝐧𝐠𝐞 =  
𝐄𝐠𝐞𝐧𝐞 𝐨𝐟 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭
𝐂𝐭𝐜𝐨𝐧𝐭𝐫𝐨𝐥−𝐂𝐭𝐭𝐫𝐞𝐚𝐭𝐞𝐝
𝐄𝐫𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐠𝐞𝐧𝐞
𝐂𝐭𝐜𝐨𝐧𝐭𝐫𝐨𝐥−𝐂𝐭𝐭𝐫𝐞𝐚𝐭𝐞𝐝
 
 
Results for the presentation as absolute data are calculated as follows by assuming, that the 
efficiency of the PCR = 2 (Equation 2). This means that amplicons are doubled in each cycle of the 
PCR reaction. Here the Ct value of the gene of interest is only referred to the internal control gene: 
 
Equation 2  𝐈𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥 𝐝𝐚𝐭𝐚𝐩𝐨𝐢𝐧𝐭 =  𝟐
−𝐂𝐭𝐫𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐠𝐞𝐧𝐞−𝐂𝐭𝐠𝐞𝐧𝐞 𝐨𝐟 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭  
 
 
3.13 SDS-PAGE and Western blot 
3.13.1 Principle 
Analysis of expression of different signalling proteins was performed using Western blot after 
separation by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were detected with 
specific antibodies and visualised by a chemiluminescence reaction with horseradish peroxidase. 
The SDS-PAGE was done according to the discontinued method of Lämmli (58). Here the proteins are 
filled in pockets in a stacking gel, were the samples are condensed to build up a continuous dye front. 
The separation takes place in a separation gel with different polyacrylamide concentration, 
depending on the size of the proteins. Due to the loading of the sample in an SDS-containing loading 
buffer, the proteins react with a constant amount of SDS. This results in protein-SDS complexes with 
the same charge/size ratio, making the proteins move in an electric field to the anode, depending on 
their size. 
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3.13.2 Sample preparation 
Cellular proteins were extracted using RIPA buffer (50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 % Triton 
X-100, 1 % sodium desoxycholate, 0.1 % SDS, 1 mM EDTA) with protease inhibitors (pepstatin, 
leupeptin, protease inhibitor cocktail, 1 mM activated Na3VO4, 1 mM NaF). Protein concentrations 
were determined using the bicinchoninic acid assay (BCA) and samples were diluted to a final 
concentration of 30 µg protein/20 µL for every gel pocket. The samples were denaturised at 95 °C for 
5 min in loading buffer, containing DTT to reduce disulphide bonds. 
3.13.3 Gel electrophoresis and Western blot 
Gels were casted starting with the separating gel requiring a polymerisation time of 15 min, being 
covered with isopropanol to build a plain phase boundary between the gels. Afterward the stacking 
gel was casted on top and combs were inserted for 30 min to form the sample pockets. After loading 
20 µL of samples, electrophoresis was run for 40 – 60 min at 200 V in electrode buffer. Afterwards 
the two gel parts were separated and the separating gel was kept in transfer buffer for the Western 
blot procedure. For quantitative detection, proteins were transferred to a PVDF membrane using a 
semi-dry tank blot method. According to the manufacturer’s instruction, the PVDF membrane was 
equilibrated 20 sec in methanol and kept in transfer buffer. Afterwards a sandwich of fiberpads, 
separating gel and PVDF membrane was built and proteins were transferred in transfer buffer for 1 h 
at 100 V and 350 mA. PVDF membrane was blocked after protein transfer with 5 % (w/v) not-fat dry 
milk powder in Tris-buffered saline (TBS) with 0.1 % (v/v) Tween-20 (≙ TBS-T) for 1 h at room 
temperature. Subsequently, the membranes were incubated overnight at 4 °C with primary 
antibodies diluted according to Table 5 and washed three times for 10 min with TBS-T. Afterwards, 
incubation with the primary antibody against the housekeeping protein for 10 min at room 
temperature followed. Subsequently after washing again twice with TBS-T for 10 min, incubation 
with a secondary HRP-conjugated antibody for 1 h at room temperature was performed before 
detection. 
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Table 5 Dilution of antibodies used for detection of proteins by 
Western blot. 
Antibody Dilution 
anti-mouse HRP 1:2000 
anti-mouse poly-HRP 1:5000 
anti-rabbit HRP 1:2000 
anti-rabbit poly-HRP 1:5000 
CCL2 1:2000 
DOK1 1:500 
goat anti-rabbit 1:10000 
HRas 1:500 
JNK3 1:333 
MDM2 1:1000 
p21 1:200 
p38 1:500 
p53-HRP 1:200 
pAtm 1:200 
SIP 1:1000 
α-Actin 1:1000 
 
 
3.13.4 Visualisation of proteins 
Antibody complexes were detected with Pierce™ ECL Western blotting Substrate, which is converted 
into a light-emitting substrate by horseradish peroxidase. Densitometric read-out was performed 
with Bio-Rad Gel Doc™ XR+ System and analysis was carried out using Image LabTM Software 5 or 
Image Analyzer 4 software. Protein signals were normalised to the housekeeping protein GAPDH or 
α-Actin. Experiments showed reproducibly that α-actin is expressed twofold higher in sensitive cells 
than in the resistant cells. Because some proteins were not detectable in untreated cells and 
therefore a fold-of-control analysis was not possible the normalisation to α-actin had to be modified 
to keep the densitometric analysis of sensitive and resistant cells comparable. Therefore those 
proteins were normalized to α-actin/2 in sensitive cells. Protein data are presented relative to 
untreated control referring each treated sample to the corresponding control on the same blot after 
normalisation. Additionally, the protein data are presented as absolute values only after 
normalisation (integrated signal intensity of each sample/control). Besides that, the concentrations 
dependent propensity was looked at, where the comparison of absolute data points between treated 
cells and control cells revealed a fold change > 2 and the error bars did not overlap. 
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3.14 Statistical analysis 
Statistical analyses were performed with Prism® V6, except for the microarray experiments. A value 
was only excluded from the analysis if Grubbs’ outlier test (extreme studentised deviate) determined 
it as an outlier, based on the significance level ɑ = 0.05. 
3.14.1 Statistical analysis of cell experiments 
EC50 values, resulting from the viability assay were assumed to be log-normally distributed (49). 
Statistical significance was in this case tested using two-sided Student’s t-test for independent 
samples. For the cisplatin accumulation and DNA-adduct formation experiments, the means of each 
independent experiment were calculated and compared between groups by a one-way ANOVA.  
To analyse whether gene/protein expression was induced by cisplatin, the differences between 
treated and untreated cells was analysed using a one-way ANOVA with Bonferroni's multiple 
comparison post-test. 
Differences were considered to be statistically significant with a p-value < 0.05 and are indicated in 
the diagrams. Experiments were performed at least in triplicates on different days and are presented 
as mean ± standard error of the mean (SEM), describing the accuracy of estimating the mean. 
3.14.2 Statistical analysis of the microarray experiment 
Statistical analysis of the array data was performed using GeneSpring GX, Vers. 13.1. For 
normalisation, data was analysed with the Linear Model for Microarray data (LIMMA), a linear 
model-based technique (59). A quantile normalisation was applied, to exclude systematic differences 
between spots of different array slides. Student’s t-test was used to calculate statistically significant 
differentially expressed genes (DEG). Cut-off p-value was < 0.05 and cut-off fold change was > 2. 
Subsequently a Gene Set Enrichment Analysis (GSEA) of all differentially expressed genes was 
performed with respect to Gene Ontology terms (GO) and the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways using HTSanalyzeR (60–63). Array data were pre-processed via 
background correction (exponential convolution method) and quantile normalisation (64, 65). GSEA 
is a widely used method comparing the mapping of genes to a defined GO term with a ranking of 
these genes, e.g. via logarithmic fold change. The GSEA method calculates a score assessing the 
statistical significance of term enrichments with respect to the ranking of genes. Dose- and 
resistance-induced gene expression changes were analysed for statistical significances again using 
LIMMA. The overall significance of the signature of differentially expressed genes was assessed via a 
global test (66). 
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4 Results 
4.1 Cisplatin cytotoxicity 
The concentration-response curves of cisplatin show differences between the sensitive and resistant 
cells. Cisplatin cytotoxicity was markedly reduced in the A549rCDDP2000 cells (pEC50 = 4.262 ± 0.171; 
mean ± SD, n=12) compared to the A549 cell line (pEC50 = 4.522 ± 0.144; n=11) after 24 h treatment. 
Based on the sigmoidal concentration-response curves, 90 % viability concentrations (EC10 values) 
were determined as 11 µM in A549 and 34 µM in A549rCDDP2000 cells (Figure 11, see Appendix A). 
These values result in a resistance factor of approximately 3. 
 
Figure 11 Representative sigmoidal concentration-response curve of cisplatin in A549 and 
A549rCDDP2000 cells. Survival is expressed in terms of % of absorbance of untreated cells as mean ± 
SD. 
 
4.2 Cellular platinum accumulation 
To assess cisplatin uptake, the intracellular platinum concentration was measured in both cell lines 
(Figure 12). The intracellular platinum content was significantly (p < 0.05) reduced in A549rCDDP2000 
cells (0.051 µmol platinum/g protein, SEM = 0.004; n = 31) compared to A549 cells (0.066 µmol 
platinum/g protein, SEM = 0.005; n = 33) after treating both cell lines with equimolar concentrations 
of 11 µM cisplatin. After treating the resistant cells with an equitoxic concentration of 34 µM, the 
accumulated platinum content raised to 0.158 µmol platinum/g protein (SEM = 0.013; n = 29), which 
was significantly (p < 0.0001) higher than the sensitive cells treated with the equitoxic concentration 
of 11 µM (see Appendix B). 
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Figure 12 Cellular platinum accumulation, n ≥ 29 in A549 and A549rCDDP2000 cells, treated with 
11 µM or 34 µM cisplatin for 24 h and presented as mean ± SEM. 
 
4.3 Cisplatin-DNA adduct formation 
After treatment with equimolar concentrations of cisplatin, the A549rCDDP2000 cells showed a lower, 
not significantly different level of Cisplatin-DNA adducts. The equitoxic concentrations led to a not 
significantly increased adduct formation in A549rCDDP2000 cells after 4 h treatment compared to A549 
cells. After 24 h treatment, resistant cells showed a similar DNA platination as after 4 h, whereas a 
not significantly increase in cisplatin-DNA adduct formation was observed in sensitive cells over time. 
These data indicate that A549rCDDP2000 cells acquired resistance mechanisms that reduce DNA 
platination, e.g. by repair mechanisms, in comparison to A549 cells. At equitoxic concentrations, 
cellular platinum accumulation was about 3-fold higher in A549rCDDP2000 cells than in A549 cells. 
However, the higher intracellular ciplatin content did not result in enhanced cisplatin-DNA adduct 
formation (Figure 13, see Appendix C). 
 
Figure 13 Cisplatin-DNA adduct formation, n = 3, in A549 and A549rCDDP2000 cells, treated with 
11 µM or 34 µM cisplatin for 4 h and 24 h presented as mean ± SEM. 
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4.4 Cell cycle analysis 
The results of the flow cytometric cell cycle analysis are shown in Figure 15. A549 cells treated with 
11 µM cisplatin showed a significant decrease of the cell fraction in the G1/G0 phase compared to 
equitoxic (34 µM) and equimolar (11 µM) cisplatin treatment in A549rCDDP2000 cells (Figure 15A). A 
more striking difference was observed in the G2/M-phase, where A549 cells treated with 11 µM 
showed a significant level of cell cycle arrest compared to that of A549rCDDP2000 cells, treated with 
either equimolar or equitoxic concentrations (Figure 15C). Thus, A549rCDDP2000 cells seem to have a 
mechanism to suppress DNA damage-induced G2/M arrest. There was a non-significant increase in 
the cell fraction found in the S-phase of resistant cells after treatment with cisplatin compared to 
that of the sensitive ones (Figure 15B, see Appendix D).  
 
 
Figure 14A/B Cell cycle analysis (n = 3) of cell fraction presented in % of the total cell population in A) 
the G1/G0-phase, B) the S-phase in A549 and A549rCDDP2000 cells as untreated controls (ctrl) or after 
treatment with 11 µM or 34 µM cisplatin presented as mean ± SEM. 
 
A) 
B) 
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Figure 15C Cell cycle analysis (n = 3) of cell fraction presented in % of the total cell population in the 
G2/M-phase in A549 and A549rCDDP2000 cells as untreated controls (ctrl) or after treatment with 11 
µM or 34 µM cisplatin presented as mean ± SEM. 
 
4.5 Apoptosis induction 
After treatment with 11 µM cisplatin, apoptosis was markedly induced in A549 cells. A549rCDDP2000 
cells exhibited significantly less apoptotic cells in response to treatment with equimolar 
concentrations of cisplatin compared to A549 cells. A549rCDDP2000 cell treatment with 34 µM 
cisplatin resulted in a tendency towards more apoptotic cells compared to 11 µM cisplatin exposure. 
However, the number of apoptotic cells was still lower compared to sensitive cells treated with the 
equitoxic concentration of 11 µM (Figure 16A). Similar results were obtained by the quantification of 
the number of cells in the SubG1-phase (Figure 16B, see Appendix E). 
C) 
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Figure 16 Apoptosis analysis with A) FITC Annexin, n ≥ 3 and B) cell count in SubG1 phase, n = 3, as 
fold change related to untreated controls in A549 and A549rCDDP2000 cells, presented as mean ± SEM. 
 
4.6 Response of the p53 system 
As the results presented in the previous three sections suggested that cisplatin-resistant cells may 
feature alterations in DNA damage response (see section 4.3, 4.4, 4.5), p53-mediated signalling was 
investigated in more detail. P53 plays a major role in DNA damage response, apoptosis and cell cycle 
regulation. Key players of the downstream signalling of p53 were investigated at the mRNA and 
protein level in order to determine differences in p53 signalling in response to cisplatin treatment 
between A549 and A549rCDDP2000 cells. As expected, because of a minor role of changes in p53 
transcription and mainly regulation on protein level (67), p53 expression was not changed after 
cisplatin treatment but showed a significantly (p < 0.01) higher baseline level in resistant cells 
compared to sensitive ones (Figure 17A). There was a significant accumulation (p < 0.05) of the total 
protein in cisplatin-treated sensitive cells compared to resistant cells treated with 11 µM cisplatin (p 
< 0.01) or with 34 µM cisplatin (p < 0.001). Absolute data revealed that only cisplatin treatment in 
sensitive cells resulted in a significant increase in protein accumulation. Equitoxic cisplatin treatment 
A) 
B) 
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induced a similar increase of p53 protein expression in A549 and A549rCDDP2000 cells (Figure 17B/C, 
see Appendix F). 
 
 
Figure 17 Analysis of p53 in A) RT-PCR (n = 3) as fold change relative to untreated control (ctrl) and 
absolute data, B) Western blot (n = 3) as fold change and integrated signal intensity normalised to 
the housekeeper α-actin in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 
cells treated with 34 µM cisplatin. 
  
C) 
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Upstream of p53, the DNA damage recognition protein Ataxia Telangiectesia mutated (Atm) protein 
showed a higher induction in relative protein level in sensitive cells compared to A549rCDDP2000 cells. 
This difference in extent of induction was, however, not significant. In sensitive cells the activation 
was significant compared to the untreated control (p < 0.05) after treatment with 11 µM cisplatin 
whereas it was not significant in resistant cells (Figure 18A, see Appendix G). 
 
 
Figure 18 Analysis of pAtm in A) Western blot (n = 3) as fold change and integrated signal intensity 
normalised to the housekeeper α-actin in A549 and A549rCDDP2000 cells, presented as mean ± SEM, 
B) one representative Western blot with A549 cells untreated, A549 cells treated with 11 µM 
cisplatin, A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and 
A549rCDDP2000 cells treated with 34 µM cisplatin. 
  
A) 
B) 
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Mouse double minute 2 homolog (MDM2) protein, a p53 target and endogenous p53 antagonist was 
significantly up-regulated at mRNA level (p < 0.05) after 24 h treatment with equitoxic cisplatin 
concentrations in both cell lines (Figure 19A). Levels of mRNA were comparable in sensitive and 
resistant cells. The level of induction in fold change compared to control was significantly higher in 
sensitive cells compared to equimolar (p < 0.001) and equitoxic (p < 0.001) treatment in resistant 
cells. No significant changes in MDM2 protein expression were observed in both cell lines after 
cisplatin treatment (Figure 19B, see Appendix H).  
 
 
Figure 19 Analysis of MDM2 in A) RT-PCR (n = 3) as fold change related to untreated controls (ctrl) 
and absolute data, B) Western blot (n = 7) as fold change and integrated signal intensity, normalised 
to the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 cells 
treated with 34 µM cisplatin. According to the manufacturer’s instruction both bands of MDM2 were 
quantified. 
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The mRNA of p21, a protein involved in regulation of the cell cycle, was significantly higher in fold 
change after 11 µM cisplatin treatment in sensitive cells (p < 0.01) and after 34 µM cisplatin 
treatment in resistant cells (p < 0.05) compared to 11 µM cisplatin treatment in resistant cells (Figure 
20A). It was significantly (p < 0.05) up-regulated at mRNA level upon all treatment conditions and in 
both cell lines. On protein level, no significant changes were observed (Figure 20B, see Appendix I). 
 
 
Figure 20 Analysis of p21 in A) RT-PCR (n = 3) as fold change related to untreated controls (ctrl) and 
absolute data, B) Western blot (n = 3) as fold change and integrated signal intensity, normalised to 
the housekeeper α-actin in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 cells 
treated with 34 µM cisplatin. 
  
C) 
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Relative mRNA levels of SIP, a stress-induced protein and another upstream activator (cofactor) of 
p53, were significantly (p < 0.05) increased in sensitive cells after treatment with cisplatin in contrast 
to to resistant cells (Figure 21A). These results were not transferred to the protein level, where no 
regulation of protein expression was observed. Baseline levels of SIP differed significantly between 
both cell lines (Figure 21B, see Appendix J). 
 
 
Figure 21 Analysis of SIP in A) RT-PCR (n = 3) as fold change relative to untreated controls (ctrl) and 
absolute data, B) Western blot (n = 5) as fold change and integrated signal intensity, normalised to 
the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot showing A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 
cells treated with 34 µM cisplatin. 
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Xeroderma pigmentosum, complementation group C (XPC) mRNA, which encodes a member of the 
nucleotide excision repair system and is a downstream effector of p53, was significantly up-regulated 
in fold change in sensitive cells after cisplatin treatment (p < 0.05). The induction of XPC mRNA 
expression was significantly stronger in sensitive cells compared to resistant cells treated with 
equimolar (p < 0.01) and equitoxic (p < 0.05) cisplatin concentrations (Figure 22A). On protein level, 
XPC showed no significant changes after treatment with cisplatin (Figure 22B, see Appendix K). 
 
 
Figure 22 Analysis of XPC in A) RT-PCR (n = 3) as fold change related to untreated controls (ctrl) and 
absolute data, B) Western blot (n = 5) as fold change and integrated signal intensity, normalised to 
the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM as well, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 
cells treated with 34 µM cisplatin. 
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The growth arrest and DNA-damage-inducible protein GADD45 alpha (GADD45a), which in general is 
a downstream effector of p53 with impact on checkpoint kinases and an inducer of cell cycle arrest, 
showed a significantly different expression upon treatment with 11 µM cisplatin in A549 cells 
compared to A549rCDDP2000 cells treated with an equimolar concentration (Figure 23A). At the 
protein level, however, no significant differences between treated and untreated cells were observed 
(Figure 23B, see Appendix L). 
 
 
Figure 23 Analysis of GADD45a in A) RT-PCR (n = 3) as fold change related to untreated controls (ctrl) 
and absolute data, B) Western blot (n = 4) as fold change and integrated signal intensity, normalised 
to the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 
cells treated with 34 µM cisplatin. 
 
C) 
A) 
B) 
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4.7 Transcriptome analysis and array validation 
4.7.1 Differentially expressed genes 
To perform a first step towards systems pharmacology, a more systematic approach was needed. 
Here a data-driven approach was chosen investigating the transcriptome of both cell lines in different 
treatment situations in a whole genome array. Processing of array data is shown in Figure 24. After 
extracting differentially expressed genes a Gene Set Enrichment Analysis (GSEA) was carried out in 
order to identify key pathways altered in response to cisplatin treatment (62). The set of 
differentially expressed genes was then reduced to those involved in the identified pathways and 
further validated via qPCR and Western blot. 
 
 
Figure 24 Flow diagram of array data processing (FDR = false discovery rate; WB = Western blot; GO 
terms = Gene ontology terms). 
 
The number of differentially expressed genes in the different treatment situations with at least 2.0 
fold up- or down-regulation and a false discovery rate of 5 % in A549 and A549rCDDP2000 cells can be 
found in Table 6.  
Identification of differentially expressed genes 
Fold change cut-off = 2.0 fold 
up- or down-regulation 
FDR = 5 % (Section 4.7.1) 
Gene Set Enrichment Analysis (GO terms) 
Notch Receptor Signalling 
Cell Surface Receptor Signalling 
VEGFR pathway 
Ras Protein Signal Transduction 
(Section 4.7.2) 
Identification of key players by overlap of pathways 
HRas, JNK3, p38, CCL2, DOK1 
(Section 4.7.3) 
Analysis of key candidates via qRT-PCR and WB 
Significant differences for HRas, JNK3, 
p38 
No significant difference for CCL2, 
DOK1  
(Section 4.8) 
Compilation of resistance-associated signalling alterations in a model (Section 4.9) 
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Table 6 Number of differentially expressed genes, compared as treatment condition vs. treatment 
control with at least 2-fold up- or down-regulation and a false discovery rate below 5 %. 
Treatment control vs. Treatment condition Number of differentially 
expressed genes 
A549, control A549rCDDP2000, control 3697 
A549, 11 µM cisplatin A549rCDDP2000, 11 µM cisplatin 4394 
A549rCDDP2000, control A549rCDDP2000, 11 µM cisplatin 27 
A549rCDDP2000, control A549rCDDP2000, 34 µM cisplatin 708 
A549, control A549, 11 µM cisplatin 1191 
A549, 11 µM cisplatin A549rCDDP2000, 34 µM cisplatin 3670 
 
The generated heat map of differentially expressed genes shows a clear clustering between the 
different treatment conditions and cell types based on an average linkage clustering using Pearson’s 
correlation distance (Figure 25).  
 
Figure 25 Heat map of the whole transcriptome, regulated genes with fold change cut-off at 2.0 and 
a false discovery rate of 5 % of all replicates in sensitive and resistant cells. Numbers above lanes 
indicate: 1, 2, 3, 4: A549 untreated control; 5, 6, 7: A549 treated with 11 µM cisplatin; 8, 9, 14, 15, 
16: A549rCDDP2000 untreated control; 10, 11, 17, 18, 19: A549rCDDP2000 treated with 11 µM cisplatin; 
12, 13, 20, 21, 22: A549rCDDP2000 treated with 34 µM cisplatin. 
 
The tree structure on top of the heat map indicates that A549 cells and A549rCDDP2000 cells cluster in 
two different groups independent of treatment. This shows that the adaptation to cisplatin over a 
long time changes the expression pattern more than a single treatment with a higher concentration. 
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In the resistant cells, the difference in expression is concentration-dependent, as cells treated with 
the higher concentration cluster on the outer right side of the heat map. Furthermore, the number of 
differentially expressed genes caused by acute cisplatin exposure is larger in sensitive cells than in 
the resistant cells, even with the higher dose (Table 6). 
The technical validation of the microarray was performed by real time qRT-PCR with 10 significantly 
up- or down-regulated genes in all three different treatment conditions using the SYBR Green 
method with the LightCycler® 480. The results of the qRT-PCR were consistent with the microarray 
data, so that they were accepted as successfully validated. As shown in Figure 26, the analysis of 
genes in real time qRT-PCR (on the right side) shows the same pattern of up-regulation and down-
regulation as the data evolved from the microarray analysis (on the left side, only significant fold 
changes depicted for visualisation) (see Appendix M). 
 
4.7.2 Gene Set Enrichment Analysis 
After the previously described identification of differentially expressed genes a Gene Set Enrichment 
Analysis (GSEA) was performed. 12 GO and KEGG terms, respectively, were found to be statistically 
significant (FDR < 5 %) associated with cisplatin treatment: actin filament bundle assembly, cell 
surface receptor signalling pathway, cytokine-mediated signalling pathway, cytoplasmic microtubule 
organisation, hematopoietic progenitor cell differentiation, negative regulation of osteoblast 
differentiation, NOTCH receptor signalling, oocyte maturation, Ras protein signal transduction 
pathway, regulation of proteolysis, response to testosterone stimulus, and VEGFR signalling pathway. 
The number of differentially expressed genes annotated with all of these 12 terms was far too large 
for further analysis. Therefore, the analysis was focused on those terms, for which a contribution to 
the mode of action of cisplatin or a possible involvement in chemoresistance has been described in 
the literature, namely the NOTCH receptor signalling (68–70), the VEGFR signalling pathway (71, 72), 
the cell surface receptor signalling pathway (71–78) and the Ras protein signal transduction pathway 
(79–82).  
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Figure 26 Comparison of array data, n = 3 (left) to PCR data, n = 3, presented as mean ± SEM (right); 
displayed as fold change with respect to untreated controls in A549 and A549rCDDP2000 cells. 
CCL2) 
SLC9A9) 
DOK1) 
p38) 
DNER) 
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4.7.3 Identification of key players 
Importantly, the four identified gene sets are not independent but share a number of differentially 
expressed genes (Figure 27). The numbers in the fields of the diagram indicate the number of genes 
which were found in the indicated pathway. The yellow sections indicate those overlapping genes 
which were found in at least two pathways and because of this were chosen for further analysis. 
 
Figure 27 Venn diagram showing differentially expressed genes annotated with respective GO and 
KEGG terms: The yellow sections indicate those genes which were chosen for validation. 
 
These shared genes comprise: HRas, p38, CCL2, DOK1, DOK2, PTK2B and a highly similar transcript 
variant, and MAPKAPK2. For further investigation, we decided to investigate only one isoform of 
DOK, DOK1, because of the high similarity between both forms. As MAPKAPK2 is directly associated 
downstream to p38 and directly regulated by p38, we decided to analyse only p38 as the 
superordinate mitogen-activated protein kinase (83–85). Both isoforms of PTK2B were not included 
in the validation because it was shown that they are mostly highly expressed in the central nervous 
system and in megakaryocytes (86, 87). Moreover, it appeared interesting to include JNK3 in further 
analysis as well, because HRas signalling reaches the nucleus via phosphorylation of JNK (88–90) and 
JNK3 was found to be differentially regulated on the microarray. This data-driven method thus 
identified the following five key players for further evaluation: HRas, JNK3, p38, CCL2 and DOK1. 
 
4.8 Protein expression of identified key players in comparison to gene expression 
After the whole-transcriptomic analysis, the identified genes were evaluated at the mRNA level by 
qPCR and at the protein level by Western blot analysis. Both, mRNA and protein levels are shown in 
Figure 28 to Figure 32 next to each other for a better comparison.  
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Expression at mRNA level of HRas, a member of the oncogenic Ras-family, was not altered after 
cisplatin exposure in both cell lines. In resistant cells, only a hint to an up-regulation after treatment 
with 34 µM cisplatin was observed (Figure 28A). At the protein level, the cisplatin-sensitive cells 
differed from resistant ones: Sensitive cells showed no changes, whereas resistant cells showed a 
significant (p < 0.05) reduction of protein content in fold change after treatment with 11 µM and 34 
µM cisplatin relative to sensitive cells after cisplatin treatment (Figure 28B, see Appendix N). 
Presented as absolute data, this reduction in protein content is visible as well. However, in this case 
the difference is not significant. 
 
 
Figure 28 Analysis of HRas in A) RT-PCR (n = 3) as fold change related to untreated controls (ctrl) and 
absolute data, B) Western blot (n = 6) as fold change and integrated signal intensity, normalised to 
the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 
cells treated with 34 µM cisplatin. 
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JNK3, a protein kinase in context of apoptosis, which is directly connected to HRas (88), was down-
regulated at the mRNA level upon all treatments. When cisplatin-resistant cells treated with high 
concentrations were compared to the low-concentration cisplatin treatment, the expression was 
significantly lower at the higher concentration. Moreover, this was also visible comparing the 
absolute data: JNK3 was significantly down-regulated at the protein level in the cisplatin-resistant 
cells treated with 34 µM cisplatin (Figure 29, see Appendix O). Remarkably, the basal mRNA level of 
JNK3 protein was significantly higher in untreated resistant cells than in the untreated sensitive ones. 
Differences at the mRNA level were not transferred to the protein level, where no changes were 
visible.  
 
 
Figure 29 Analysis of JNK3 in A) RT-PCR (n = 3) as fold change related to untreated controls (ctrl) and 
absolute data, B) Western blot (n = 9) as fold change and integrated signal intensity, normalised to 
the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 
cells treated with 34 µM cisplatin. 
C) 
A) 
B) 
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P38, a kinase involved in stress response and cell cycle alterations, was not differentially expressed at 
the mRNA level upon cisplatin treatment. Under equitoxic and equimolar treatment conditions in 
cisplatin-resistant cells, no up-regulation was observed (Figure 30A). Remarkably, the basal level of 
p38 protein was significantly higher in untreated resistant cells than in the untreated sensitive ones. 
No significant difference between treatments was found on protein level (Figure 30B, see Appendix 
P). 
 
 
Figure 30 Analysis of p38 in A) RT-PCR (n = 3) as fold change related to untreated controls (ctrl) and 
absolute data, B) Western blot (n = 6) as fold change and integrated signal intensity, normalised to 
the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 
cells treated with 34 µM cisplatin. 
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CCL2, a cytokine gene associated with invasion and metastasis, is connected to p38 (91, 92). No 
significant regulation either at mRNA or protein level could be observed in treated cells (Figure 31, 
see Appendix Q). 
 
Figure 31 Analysis of CCL2 in A) RT-PCR (n = 3) as fold change related to untreated controls (ctrl) and 
absolute data, B) Western blot (n = 4) as fold change and integrated signal intensity, normalised to 
the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 
cells treated with 34 µM cisplatin. 
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DOK1 is known as a tumour suppressor protein in epithelial ovarian cancer and negative regulator of 
tyrosine kinases in mitogen-activated kinase signalling (93). Several studies describe DOK1 as one of 
the upstream regulators of the Ras protein family (93, 94). Upon cisplatin treatment this candidate 
was regulated neither on mRNA nor on protein level in our study (Figure 32, see Appendix R).  
 
Figure 32 Analysis of DOK1 in A) RT-PCR (n = 3) as fold change related to untreated controls and 
absolute data, B) Western blot (n ≤ 8) as fold change and integrated signal intensity, normalised to 
the housekeeper GAPDH in A549 and A549rCDDP2000 cells, presented as mean ± SEM, C) one 
representative Western blot with A549 cells untreated, A549 cells treated with 11 µM cisplatin, 
A549rCDDP2000 cells untreated, A549rCDDP2000 cells treated with 11 µM cisplatin and A549rCDDP2000 
cells treated with 34 µM cisplatin. 
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4.9 Proposed model of resistance-associated signalling alterations 
Cisplatin leads to DNA damage by forming DNA adducts. This toxic insult triggers cellular activation of 
several different pathways leading to survival or apoptosis, depending on the severity and extent of 
DNA damage. In chemoresistant cancer cells, these pathways are considered to be significantly 
dysregulated as one major mechanism of acquired resistance. Using the absolute data derived from 
the analysis of the DNA damage pathways and the data-driven approach based on the whole genome 
array, a preliminary model of resistance-associated signalling alteration is proposed to explain the 
observed differences in cell cycle analysis (Figure 33). Here significant differences among groups at 
the mRNA level are indicated in red and at the protein level in green. Differences resulting from 24 h 
treatment with cisplatin are indicated by coloured arrows, differences in basal levels between 
sensitive and resistant control cells are indicated by coloured forms in the background. Where the 
comparison of absolute data points between treated cells and control cells revealed a fold change > 2 
and the error bars did not overlap, we included the propensity of a difference into the model, 
indicated with dotted arrows in the same colour scheme as mentioned before: 
• P53 and pAtm showed significantly higher protein abundance in sensitive cells after cisplatin 
treatment (green arrows). Both additionally showed propensities for a concentration-
dependent activation in resistant cells (green dotted arrows). P53 additionally had a higher 
basal mRNA level in resistant cells compared to sensitive ones (red background). 
• MDM2 and P21 were equivalently activated at the mRNA level in both cells lines after 
cisplatin treatment (both indicated with red arrows).  
• SIP activation was significantly increased at the mRNA level in sensitive cells after treatment 
(red arrows) and showed a higher basal protein level in resistant cells than in sensitive ones 
without treatment (green background). 
• XPC only showed a propensity of a higher mRNA level in sensitive treated cells compared to 
the corresponding control. GADD45a showed this propensity in both cell lines after 
treatment with cisplatin (both indicated with red dotted arrows).  
Two genes derived from the whole genome analysis, showing significant differences between both 
cell lines can be associated to the signalling connections proposed between the identified proteins 
from the DNA damage pathway.  
• JNK3, a mitogen activated protein kinase involved in apoptosis (95–100) is downregulated at 
the mRNA level after cisplatin treatment in resistant cells (red arrows). There was only a 
propensity in the sensitive cells (red dotted arrow). JNK3 showed already a higher mRNA 
level in the untreated resistant cells compared to untreated sensitive cells (red background).  
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• P38, also a regulator of p53 (101–103), showed a significantly higher basal level in untreated 
cisplatin-resistant cells compared to untreated sensitive cells (red background).  
CCL2, DOK1 and HRas were not included into the model, as the results did not reveal any 
significant differences following cisplatin treatment. 
 
 
Figure 33  Model of resistance-associated signalling alterations compiling significant expression changes after 
cisplatin treatment in A) A549 and B) A549rCDDP2000 cells based on mRNA data (red) or protein data 
(green). Significant changes after 24 h cisplatin treatment are indicated with arrows (,), significant 
differences of basal levels between the two cell lines are indicated with coloured forms in the 
background. Dotted arrows display propensities for differences in the same colour scheme. 
  
A) B) 
Discussion 67 
5 Discussion 
5.1 Systems pharmacology approach 
This is our first step towards systems pharmacology, which connects several key players with each 
other, based on both transcriptome and proteome data. We think that a systems approach may be 
superior to address the problem of resistance to cisplatin. Contrary to approaches known from the 
literature, which mainly identify single proteins or a list of affected pathways (104–106) without 
displaying any functional connections, our approach establishes first steps depicting a part of the 
whole cell system. Additionally, we combined the analysis to the transcriptome and the protein level. 
Galuzzi et al. studied the mRNA expression profile in cisplatin-sensitive cells without comparing them 
to the corresponding resistant ones and displaying a signalling network (107). They analysed the 
transcriptional changes after treatment with cisplatin in comparison to those after treatment with 
two known inducers of mitochondrial apoptosis, C2-ceramide and cadmium dichloride. They found, 
that cisplatin exerts apoptosis in a different way, through genes that are not induced in cell death 
signalling after treatment with C2-ceramide and cadmium dichloride. Among 19 transcriptional 
modulations, no overlap with our findings was found. The authors were also quite uncertain about 
the results, as unexpectedly little overlap was observed with 85 cisplatin response modifiers that the 
authors had previously reported in a siRNA screening (108). Zeng et al. compared the proteome 
between A549 and A549/CDDP cells and identified 12 cisplatin resistance-related proteins, without 
compiling the data in a network and discussing interactions (109). The identified proteins were 
different to our results, as the authors analysed the proteome level and we based our protein 
analysis on previously found differences at mRNA level. Here several factors like duration of 
treatment, other mechanisms of activation than translation may account for finding other candidates 
in our analysis. Yang et al. analysed the RNA expression profile of lung carcinoma cells and built up a 
signalling network between those specific RNAs but did not connect these data with protein 
expression in their cell system. Besides identifying a huge number of differentially expressed genes in 
A549 and A549/CDDP cells, the authors conclude that cisplatin resistance is also related to changes in 
non-coding RNAs. Interestingly, some of the 1471 identified mRNAs code for closely related proteins 
to those identified in our study, like CCL2 or several MAP-Kinases (110).  
Consciously, we here follow a data-driven top-down approach, which involves iterative filtering of 
the massive amount of data of the whole genome microarray. This was done by statistical means 
without limiting the results by a predefined hypothesis. Here, the reduction was done by choosing 
those differentially expressed genes, which occur simultaneously in different GO and KEGG terms. 
This increased the a priori chance of these genes to play a major role in cisplatin-dependent response 
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of the cell. On the other hand, this way of reduction of genes could have led to the loss of relevant 
genes. The GO and KEGG terms, which were found by GSEA but not included into our study could be 
interesting for further analysis, as they may reveal completely new and unknown mechanisms of cell 
signalling alterations in response to cisplatin treatment. 
  
5.2 Cell system 
To elucidate the molecular mechanisms underlying acquired cisplatin resistance, we investigated the 
NSCLC cell line A549 and its cisplatin-resistant sub-line A549rCDDP2000. The resistant cells displayed a 
twofold higher EC50 value, reduced apoptosis, as well as alterations in intracellular platinum 
accumulation and DNA platination. The results displayed here are consistent with the two-fold lower 
sensitivity of resistant tumour cells to cisplatin in clinical studies for ovarian cancer (111) and the 
resistance in A549 cells measured by Yang et al. (112).  
The EC10 concentrations used in the experiments were precautionary to prevent effects 
superimposing resistance mechanisms. Cisplatin concentrations used in our experiments were 
comparable to the clinically attainable concentrations. Milward et al. showed that patients treated 
with 75 – 100 mg/m2 cisplatin in combination with docetaxel showed a Cmax range from 8.1 µM to 
28.9 µM total platinum (113). Tegeder et al. could determine cisplatin tumour concentration after 
intra-arterial administration as 37.6 ± 8.8 µmol/L (mean ± SEM, 11.3 ± 2.7 µg/mL) (114). 
To compensate the effects of altered influx of cisplatin in resistant cells, equitoxic concentrations 
were studied showing similar Pt-DNA adduct formation but differences in drug accumulation. We 
previously demonstrated in other cell lines that reduced cisplatin accumulation may be one source of 
chemoresistance (115). At equimolar concentrations, platinum-DNA adduct formation was not 
significantly lower in A549rCDDP2000 cells after 4 h treatment compared to sensitive cells and 
increased over time in A549 cells only. Equitoxic concentrations led to a subproportional increase of 
DNA-adduct levels in resistant cells compared to the intracellular platinum accumulation. After 24 h 
treatment with equitoxic concentrations, DNA adduct levels were similar in A549 and A549rCDDP2000 
cells suggesting that resistant cells exhibit a higher DNA-repair capacity than sensitive cells, as 
intracellular platinum accumulation was significantly higher in resistant cells. Other explanations for 
similar DNA-platination levels despite higher cellular platinum accumulation in A549rCDDP2000 at 
equitoxic concentrations are increased sequestration in vesicles and an increased drug inactivation 
compared to the sensitive cells. Glutathione or for instance enzymes structurally similar to 
glutathione are known to act as detoxification agents for cisplatin (13, 27, 116–119).  
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5.3 DNA damage and repair 
Although equitoxic cisplatin concentrations resulted in similar extent of DNA damage in sensitive and 
resistant cells, the cellular response showed significant differences. Apoptosis was only induced in 
sensitive cells pointing to an altered DNA-damage response in resistant cells. It was previously shown 
that resistant NSCLC cells have a higher repair capacity (120, 121). The impact of this phenomenon 
leading to resistance was documented in several studies. Chen et al. conducted a meta-analysis, 
where objective response or median survival were correlated with ERCC1 as a marker for DNA-repair 
capacity (27). The results showed that patients with high repair capacity featuring high expression of 
ERCC1 suffer from low median survival. The authors suggested ERCC1 expression as a marker for 
chemoresistance against cisplatin. Mountzios et al. drew a similar conclusion based on the 
observation that the benefit from cisplatin treatment was higher in patients with low expression of 
ERCC1 (122). Rosell et al. showed that NSCLC patients with a high DNA repair capacity had a poor 
survival after a combination treatment with cisplatin (123). This is in agreement with our results 
regarding phosphorylation of Atm, which is responsible for the recognition of DNA double-strand 
breaks, finally leading to a G2/M arrest in sensitive cells. As expected, this protein shows nearly no 
activity in untreated control cells. 
This DNA damage leads to activation of SIP which is a cofactor of p53. SIP is capable of modulating 
p53 activation and leads to the expression of antiproliferative and proapoptotic target genes of p53, 
like p21 (124, 125). This signalling pathway is activated by several different stress inducers in tumour 
cells (124, 126, 127). Activation of SIP by cisplatin promoting cell death was also shown in other cell 
lines (128). In line with this work SIP is activated after treatment for 24 h with cisplatin at the mRNA 
level in sensitive cells. Although showing higher basal SIP protein abundance, this mechanism seems 
to be blunted in resistant cells. 
Furthermore, DNA damage tolerance may contribute to the cisplatin resistance of A549rCDDP2000 
cells. Cisplatin treatment significantly increased expression of XPC in fold change, a protein 
downstream of p53 and crucial for DNA damage recognition, in sensitive cells relative to resistant 
ones. This suggests higher activation of the global genome repair pathway and therefore a lower 
tolerance to cisplatin-DNA adducts in A549 cells. Beside its role in DNA damage recognition, XPC 
plays a major role in altering the cell cycle after treatment with cisplatin. In XPC-deficient cell lines, 
the p53 pathway is altered and cell cycle arrest, DNA repair and apoptosis are attenuated (129). XPC-
deficient transgenic mice are highly predisposed to several types of cancer (130) and XPC/GADD45a 
knockout in mice leads to development of lung tumours (131). XPC expression is also reduced in the 
tumour tissue of resistant patients compared to normal lung tissue (132). Additionally, reduced XPC 
mRNA was suggested to predict a poor outcome for patients with NSCLC (133). Weaver et al. showed 
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that XPC correlates with chemoresistance in NSCLC (134). GADD45a, also enhancing NER (135), had a 
higher fold change in sensitive A549 cells after cisplatin treatment compared to XPC. This may 
support the hypothesis that the NER response is induced to a lower level in resistant cells. Overall, it 
can be seen that sensitive cells show stronger reactions in mRNA expression than resistant cells. They 
again seem to be more robust. 
 
5.4 Cell cycle alterations 
GADD45a is involved in cell cycle regulation and responsible for a G2/M arrest to enhance DNA repair 
(136). If the reparation process is successful, the cell is able to survive; otherwise the cell is send into 
apoptosis. GADD45a may contribute to the G2/M-phase cell cycle arrest in A549 cells in response to 
treatment with cisplatin. Fold change of GADD45a mRNA was significantly different in A549rCDDP2000 
cells treated with 11 µM cisplatin compared to sensitive cells after treatment. This could also be seen 
in the absolute data on mRNA level but, however, did not translate into a significant difference in 
GADD45a protein levels at the time point studied. Reduced expression of GADD45a has been 
associated with poor survival in oesophageal cancer patients (137). The cell cycle alterations are in 
agreement with previously published work (138), showing that tumour initiating cells are prone to 
less G2/M-arrest after DNA-damaging treatment. Horibe et al. showed that cisplatin resistance is 
linked to loss of G2/M-arrest in cisplatin-resistant cells (139). The p53 target gene product p21 that 
induces cell cycle arrest in G2/M-phase was up-regulated in sensitive and resistant cells after 
treatment with cisplatin. Comparing the fold change to control, in sensitive and resistant cells treated 
with equitoxic cisplatin concentrations a higher expression of p21 was observed than in resistant 
cells treated with 11 µM cisplatin. This suggests a p53-mediated cell cycle arrest in sensitive cells that 
is less active in cisplatin-resistant cells. Activation of this mechanism needs higher concentrations in 
resistant cells. We assume that this adaptation to cisplatin treatment is part of the resistance 
phenotype in A549rCDDP2000 cells. 
MDM2 ubiquitinates p53 and regulates its activity and degradation in an autoregulatory feedback 
loop. MDM2 was significantly activated at the mRNA level in cisplatin-treated cells at equitoxic 
concentrations. The extent of activation in A549 cells was significantly higher in relation to 
A549rCDDP2000 cells. At the protein level, no significant differences could be observed. One result of 
ubiquitination by MDM2 is destabilization of p53, diminishing the reservoir of p53 which could be 
easily and quickly activated if needed. This existing balance between MDM2 and ubiquitinated p53 
would be disturbed if MDM2 protein levels are altered rapidly with high amplitudes, e.g. massive 
over-expression in short time. In consequence, a significant reduction of MDM2 would lead to an 
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overimposing activity of p53, which is physiologically unfavourable in resistant tumour cells. To avoid 
this, only moderate changes take place in this equilibrium. As MDM2 is also a downstream 
transcriptional target of p53 (140), p53 activation via phosphorylation, ubiquitination etc. may be 
altered in resistant cells. In the future, a closer look at the activation status of p53 after treatment 
with cisplatin should be taken, as this may be a key difference in p53 regulation influencing sensitivity 
against cisplatin. 
 
5.5 Role of the identified key players 
Cisplatin leads to DNA damage by forming Pt-DNA adducts. This toxic insult triggers activation of 
several different pathways for survival or apoptosis, depending on the extent of DNA damage. In 
chemoresistant cancer cells, these pathways are considered to be significantly dysregulated. HRas is 
one of the genes of the Ras oncogenic family and due to its prominent activity in the ERK1/2-
pathway likely associated with cisplatin resistance. In contrast to our results, several studies revealed 
that HRas is activated by cisplatin treatment (79, 141, 142). Activating mutations of the Ras family in 
several cancer entities were held responsible for tumour development (141, 143–145). Reduced 
levels of HRas in our case could be responsible for the reduced levels of activated JNK. Several 
working groups showed that Ras signals, altering gene expression (e.g. fos- and jun- genes), reach the 
nucleus via phosphorylation of JNK (88–90). The observed reduced levels of JNK3 and potentially less 
phosphorylated JNK3 after treatment with equitoxic cisplatin concentrations could lead to reduced 
activation of p53 in the resistant cells. Fuchs et al. showed that JNK signalling is able to stabilise p53 
by hindering MDM2 binding, increasing p53 activation and supporting p53-induced apoptosis (146). 
Additionally, JNKs appear to phosphorylate p53 at various sites after DNA damage (147). It is not 
really clear, why resistant cells show higher basal levels of JNK3 without any treatment. It was shown 
in mantle cell lymphoma that consecutive expression of JNK is required to promote proliferation 
(148). Alternatively, this could be an effect of the treatment with sub-toxic concentrations of cisplatin 
to maintain the resistant phenotype. In our case, this effect was abolished by cisplatin treatment for 
24 h. 
Another upstream effector of p53 is p38 which is not regulated at the mRNA level in both cells 
treated with cisplatin. Also in the Western blot experiments, no regulation under the different 
treatment conditions were seen in both cell lines. This result is in line with previously reported work, 
where no difference in expression of p38 protein was seen after cisplatin treatment (149–151). 
Remarkably, higher basal levels of p38 were observed in untreated resistant cells compared to 
untreated sensitive ones. This suggests that the longer lasting treatment with sub-toxic 
concentrations of cisplatin to maintain the resistance phenotype seems to have a greater effect on 
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p38 as the treatment with cisplatin for 24 h. This phenomenon in general is not uncommon in 
resistant cancer cells, where high levels of p38 were associated with poor prognosis (152). It seems 
that this difference at the mRNA level is not translated to the protein level at the time point 
measured in the conducted experiments. Future experiments should focus on phosphorylated p38, 
as activation could take place only by phosphorylation at the protein level. Activated p38 itself is 
capable of phosphorylating and activating p53 (153). 
A previous study showed that expression of CCL2 in ovarian cancer cells seems to correlate with 
chemotherapy response and is reduced in cisplatin-resistant cells (154). Another study revealed that 
CCL2 expression rises after treatment with cisplatin (155). This effect was not observed in our cell 
line pair. Additionally, in contrast to our results, Ho et al. showed that the expression of CCL2 is 
induced by p38 (156). After treatment with equitoxic cisplatin concentrations, the results could 
suggest an increase of mRNA abundance in both cell lines. Due to the high variability of the results, 
significance was not reached.  
According to the literature, DOK1 could play a role in response to cisplatin treatment as down-
regulation of this protein increased cisplatin resistance in ovarian cancer cells (93). This could not be 
confirmed in our experiments, thus, the role of DOK1 remains unclear. 
Following these results, proteins exhibiting significant differences (JNK3, p38) between both cell lines 
were included in our newly developed model. In contrast, those proteins where further evaluation is 
needed to explore their role in chemoresistance (CCL2, DOK1, HRas) were not included. 
 
5.6 Proposed model of resistance-associated signalling alterations  
Based on the results presented above we have developed a signalling model (Figure 33), which 
displays possible connections between the key players of cellular response to cisplatin exposure. We 
included knowledge-based evidence to draw the connections between our experimental results. This 
model reveals mechanisms accounting for a different reaction of the sensitive and resistant NSCLC 
cells to cisplatin treatment. It provides an overview of the possible roles of several cellular proteins; 
however, it represents only a very small part of the whole picture inside the cell. Results from mRNA 
level could not always be transferred to the protein level. This could be a matter of the time point of 
measurement. pAtm and p53 are activated after cisplatin exposure on protein level in sensitive cells, 
triggering G2/M arrest. Activation at the mRNA level takes place at an earlier stage. P53 is now 
already capable of acting as a transcription factor to activate the other proteins in the signalling 
model. These are consequently activated at the mRNA level but possibly not yet at the protein level. 
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This lack of correlation between mRNA and protein data was discussed already in literature. A review 
from 2009 summarises several mechanisms possibly responsible for the quantitative differences of 
transcriptome and proteome: (1) post-transcriptional parameters, (2) post-translational parameters, 
and (3) noise and experimental error. It is still not clearly determinable to which extent biological 
factors, translation efficiency or protein half-life have impact on the mRNA levels (157). Half-life of 
proteins for example massively influences the correlation between mRNA and protein abundance as 
it may range between seconds and hours. An analysis in a space- and time- dependent manner could 
gain more insights and should be performed in the future. The model presented here is thus not 
comprehensive and can be extended by further players. Nevertheless, it serves as a good starting 
point for a systems pharmacology approach aiming at getting a full picture of protein interactions in 
the intracellular signalling network. 
The greatest strength of the model is that the gene and protein alterations in the model are all based 
on experimental data. Within the model we displayed connections between the different candidates, 
which could serve as the origin for creating further hypotheses and for further investigations of the 
proteome. This could be limited by the fact that the model is so far not comprehensive and needs to 
be extended by further proteins, which could additionally account for the effects on cell cycle and 
apoptosis. In our study, we had to reduce the number of candidate genes and have so far not been 
able to process any distinct perturbations in the signalling network. This may be the focus of further 
projects based on these investigations. 
In the future, our model should aim at depicting the whole proteome and transcriptome, allowing 
the description of the response of all relevant signalling pathways to cisplatin exposure. Thus, 
mathematical models could make it possible to forecast the effect of specific perturbations on the 
system, serving as a starting point for the development of novel therapeutic strategies. 
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6 Conclusions 
The results of this work indicate clear differences between the response of cisplatin-resistant 
A549rCDDP2000 and sensitive A549 cells to cisplatin treatment leading to the following conclusions:  
- At equitoxic concentrations, cellular platinum accumulation was about 3-fold higher in 
A549rCDDP2000 cells than in A549 cells. However, these increased intracellular cisplatin 
concentration did not result in enhanced cisplatin-DNA adduct formation. These data 
indicate that A549rCDDP2000 cells acquired resistance mechanisms that reduce DNA-
platination, e.g. by repair mechanisms, in comparison to A549 cells. 
- A549rCDDP2000 cells showed reduced apoptosis and a lack of G2/M arrest compared to A549 
cells. Different key candidates could be found to account for these differences: 
o p53 and pAtm play a major role in the induction of G2/M arrest and apoptosis in 
A549 cells as they are significantly induced only in these cells at the protein level; 
o DNA damage recognition and signalling genes MDM2, XPC, SIP, p21 and GADD45a 
are induced by cisplatin at the mRNA level in sensitive cells to a higher extent as in 
resistant cells, where no or a reduced activation was observed;  
o JNK3 activation is reduced in resistant cells after cisplatin treatment compared to 
basal protein abundance which is significantly higher in untreated resistant cells 
compared to sensitive ones; 
o p38 only shows a higher basal mRNA level in resistant cells than in sensitive ones.  
- The data-driven approach is appropriate to reduce the massive amount of data derived from 
a whole genome screening and to identify key candidates contributing to cisplatin resistance. 
- In this work, the first step towards a systems pharmacology approach to cisplatin resistance 
has been taken and can be put forward in future experiments. A model has been built up 
describing resistance-associated signalling alterations in both cell lines. This model helps to 
comprehend how differences in gene and protein expression influence the G2/M arrest and 
apoptosis and contribute to cisplatin resistance. 
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7 Outlook 
The results of this thesis indicate that several key players are likely to be involved in cisplatin 
resistance in NSCLC cells at the transcriptome and proteome level, influencing apoptosis and cell 
cycle control. In future experiments, the analysis of the whole genome array should aim to include 
more involved players at the transcriptome level. Here, other overlaps of the identified GO terms or 
genes belonging to other GO terms should be evaluated more closely. Furthermore, connections 
between the identified players could be analysed in detail using targeted perturbations of our 
network. For this purpose, inhibitors of individual proteins or their knockdown would reveal their 
contribution to the whole network and its influence on other genes or proteins, respectively. In this 
piece of work, the cell lines were analysed at a defined time point. Additional work would be needed 
to characterise the kinetics of alterations in gene or protein expression in the network. Some changes 
in reaction to cisplatin, e.g. in the transcriptome, occur earlier than others, e.g. in the metabolome. 
Here, the focus at the vertical level (e.g. genome, transcriptome or proteome) in the systematic 
approach should be considered in defining the perfect time point for the experiments. Other aspects 
of resistance development could be revealed by investigating different stages during the 
development of the cisplatin-resistant cell line. Here, the analysis should be executed at every stage 
during the adaption of the parental cell line to cisplatin. Another focus could be placed at the protein 
level, where not only translation leads to active proteins but also phosphorylation activates several 
players. The analysis of the activation status could shed light on the mechanisms of resistance. In 
order to follow the systems pharmacology path, other levels of the cell physiology could be added on 
top of the defined model. 
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8 Summary 
The efficacy of cisplatin-based chemotherapy in cancer is limited by the occurrence of innate and 
acquired drug resistance. In order to better understand the mechanisms underlying acquired 
cisplatin resistance, the adenocarcinoma-derived non-small cell lung cancer (NSCLC) cell line A549 
and its cisplatin-resistant sub-line A549rCDDP2000 were compared with regard to cellular platinum 
accumulation, DNA-adduct formation, cell cycle alterations, apoptosis induction and activation of key 
players of DNA-damage response.  
In A549rCDDP2000 cells, the cisplatin-induced G2/M cell cycle arrest was lacking and apoptosis was 
significantly reduced compared to A549 cells, although equitoxic cisplatin concentrations resulted in 
comparable platinum-DNA adduct levels. These differences were accompanied by changes in the 
expression of proteins involved in DNA-damage response. In A549 cells, equimolar cisplatin exposure 
induced the expression of genes coding for proteins mediating G2/M arrest and apoptosis (MDM2, 
p21, XPC, SIP and GADD45a) to a higher extent as in resistant cells. This was underlined by 
significantly higher protein levels of pAtm and p53 in A549 cells after cisplatin treatment compared 
to the respective untreated controls.  
Additionally, a data-driven method was used to identify further key candidates responsible for the 
different response of the two cell lines to the drug. The cellular transcriptome was screened for 
relevant gene candidates using a whole genome array. By combining statistical methods with 
available gene annotation without previously defined hypothesis, HRas, JNK3, p38, CCL2 and DOK1 
were identified as genes relevant for cisplatin resistance. These genes were further analysed at the 
transcriptome and proteome level to introduce a more systematic approach on different stages of 
cell signalling. Upon cisplatin exposure, JNK3 showed a lower mRNA expression only in A549rCDDP2000 
cells. In addition to these effects, p53, JNK3 and p38 showed higher basal mRNA abundance in 
resistant cells compared to the sensitive cells. This circumstance was also observed with SIP at the 
protein level and suggests a relevant long-lasting effect caused during the development of resistance. 
All results were compiled in a preliminary model of resistance-associated signalling alterations.  
In conclusion, these findings suggest that acquired resistance of NSCLC cells against cisplatin is a 
consequence of altered signalling of the identified proteins leading to reduced G2/M cell cycle arrest 
and apoptosis. 
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Appendix A 
Cisplatin cytotoxicity (MTT) 
Values of a representative sigmoidal concentration-response curve of cisplatin in A549 and 
A549rCDDP2000 cells. Survival is expressed in terms of % of absorbance of untreated cells as mean ± 
SD. 
 A549 A549rCDDP2000 
 Absorption [%] Absorption [units] Absorption [%] Absorption [units] 
log [conc.] Mean SD Mean SD Mean SD Mean SD 
control 100.0 4.1 0.508 0.021 100.0 1.4 0.464 0.007 
-6.301 107.2 8.6 0.544 0.044 91.2 1.1 0.423 0.005 
-6.000 101.5 3.0 0.516 0.015 100.2 3.1 0.465 0.014 
-5.301 107.7 3.8 0.547 0.019 98.3 4.1 0.456 0.019 
-5.000 97.2 3.6 0.494 0.018 98.3 11.0 0.456 0.051 
-4.523 40.4 3.9 0.205 0.020 89.4 3.1 0.414 0.014 
-4.301 24.7 4.4 0.125 0.023 63.8 6.4 0.296 0.030 
-4.155 23.4 2.5 0.119 0.012 37.0 5.2 0.171 0.024 
-4.000 20.5 2.2 0.104 0.011 16.8 1.4 0.078 0.007 
-3.301 12.1 0.4 0.061 0.002 9.4 0.9 0.044 0.004 
 
Sensitivity of A549 and A549rCDDP2000 cells towards cisplatin expressed as pEC50 (results of different 
testing days, n = 11-12). 
Cell line A549 A549rCDDP2000 
pEC50 -4.744 -4.667 
 -4.554 -4.392 
 -4.537 -4.234 
 -4.671 -4.261 
 -4.248 -4.024 
 -4.329 -4.093 
 -4.662 -4.066 
 -4.500 -4.349 
 -4.487 -4.307 
 -4.511 -4.266 
 -4.498 -4.288 
  -4.196 
Mean (SD) -4.522 (0.144) -4.626 (0.171) 
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Appendix B 
Cellular platinum accumulation 
Cellular platinum accumulation in A549 and A549rCDDP2000 cells, treated with 11 μM or 34 μM 
cisplatin (results of different testing days, n = 29-33). 
Cell line A549 A549rCDDP2000 
Treatment concentration 11 µM 11 µM 34 µM 
Cellular platinum accumulation 0.108 0.083 0.212 
[µmol platinum/g protein] 0.099 0.074 0.239 
 0.108 0.105 0.257 
 0.119 0.079 0.134 
 0.103 0.057 0.128 
 0.110 0.049 0.206 
 0.083 0.059 0.198 
 0.074 0.079 0.212 
 0.078 0.073 0.207 
 0.096 0.076 0.230 
 0.087 0.046 0.156 
 0.092 0.080 0.233 
 0.062 0.061 0.250 
 0.074 0.066 0.271 
 0.071 0.064 0.104 
 0.072 0.054 0.198 
 0.100 0.035 0.217 
 0.096 0.039 0.174 
 0.030 0.042 0.155 
 0.038 0.038 0.179 
 0.050 0.039 0.067 
 0.041 0.043 0.070 
 0.052 0.025 0.085 
 0.053 0.019 0.075 
 0.026 0.037 0.068 
 0.029 0.025 0.066 
 0.031 0.030 0.068 
 0.029 0.016 0.059 
 0.034 0.023 0.072 
 0.037 0.023  
 0.030 0.034  
 0.034   
 0.036   
Mean (SEM) 0.066 (0.005) 0.051 (0.004) 0.158 (0.013) 
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Appendix C 
Cisplatin-DNA adduct formation 
Cisplatin-DNA adduct formation in A549 and A549rCDDP2000 cells, treated with 11 μM or 34 μM 
cisplatin for 4h and 24h as integrated signal intensity (results of different testing days, n = 3). 
Cell line A549 A549rCDDP2000 
Treatment duration 4 h 24 h 
Treatment 
concentration 
11 µM 11 µM 34 µM 11 µM 11 µM 34 µM 
 12.74 6.83 20.12 6.75 3.45 7.55 
 13.91 8.56 11.39 30.87 12.13 23.14 
 12.65 10.81 25.60 22.12 8.04 20.78 
Mean (SEM) 13.10 (0.41) 8.73 (1.15) 19.04 (4.14) 19.91 (7.05) 7.87 (2.51) 17.16 (4.85) 
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Appendix D 
Cell cycle analysis 
Cell fraction in % in G1/G0-phase, S-phase and G2/M-phase in A549 and A549rCDDP2000 cells (results of 
different testing days, n = 3-5). 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
Cell phase Cell fraction [%] Cell fraction [%] Cell fraction [%] Cell fraction [%] Cell fraction [%] 
G1/G0 70.87 25.82 67.46 40.46 47.78 
 72.30 18.59 66.79 50.97 47.58 
 69.25 11.87 72.82 58.25 52.56 
 68.38 11.68   50.54 
 75.82 50.13   50.52 
 75.89 47.38   51.94 
Mean (SEM) 72.09 (1.31) 27.58 (7.03) 69.02 (1.91) 49.89 (5.16) 50.15 (0.85) 
S 11.39 9.87 9.86 27.54 10.77 
 7.81 8.66 13.35 21.43 16.07 
 12.13 10.21 10.70 17.67 15.50 
 12.50 6.68   13.23 
 8.39 22.23   19.96 
 9.92 24.91   15.98 
Mean (SEM) 10.36 (0.80) 13.76 (3.16) 11.30 (1.05) 22.21 (2.88) 15.25 (1.26) 
G2/M 14.12 44.50 11.07 11.17 4.56 
 15.36 54.99 10.69 10.43 4.13 
 15.80 62.10 5.47 9.04 6.55 
 16.61 62.74   6.26 
 11.94 11.81   5.28 
 11.14 12.93   6.45 
Mean (SEM) 14.16 (0.90) 41.51 (9.60) 9.08 (1.81) 10.21 (0.62) 5.54 (0.42) 
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Appendix E 
Apoptosis induction 
Apoptosis analysis with FITC Annexin (n = 3-4) and cell count in the SubG1-phase (n = 3-6) as fold 
change related to untreated controls in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment concentration 11 µM 11 µM 34 µM 
FITC-Annexin [fold change to untreated control] 
 6.922 2.141 4.956 
 4.994 2.114 2.811 
 5.649 1.027 3.374 
  2.516  
Mean (SEM) 5.856 (0.566) 1.950 (0.321) 3.714 (0.642) 
SubG1-phase [fold change to untreated control] 
 5.470 1.948 3.347 
 4.190 1.672 3.048 
 5.296 1.380 2.288 
 7.112   
 3.973   
 4.599   
Mean (SEM) 5.107 (0.468) 1.667 (0.164) 2.894 (0.315) 
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Appendix F 
p53 
Results of p53 in real-time RT-PCR (n = 3) as fold change relative to untreated control using the  ΔΔCp 
method and absolute data calculated using the ΔCp method, and densitometric protein results in 
Western blot (n = 3) as fold change and integrated signal intensity; normalised to the housekeeper α-
actin in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  1.015  1.140 0.979 
  1.438  0.952 0.806 
  0.907  1.024 1.227 
Mean (SEM)  1.120 (0.162)  1.038 (0.055) 1.004 (0.122) 
mRNA (absolute data) 
 0.024 0.024 0.041 0.047 0.040 
 0.022 0.032 0.051 0.048 0.041 
 0.026 0.023 0.045 0.046 0.055 
Mean (SEM) 0.024 (0.001) 0.026 (0.003) 0.046 (0.003) 0.047 (0.001) 0.045 (0.005) 
Protein (fold change relative to untreated control) 
  11.44  2.32 6.64 
  11.05  2.55 3.19 
  9.24  1.37 4.34 
Mean (SEM)  10.58 (0.68)  2.08 (0.36) 4.72 (1.01) 
Protein (integrated signal intensity) 
 0.48 5.54 0.90 2.08 5.95 
 0.40 4.48 1.22 3.11 3.89 
 0.25 2.32 0.55 0.75 2.39 
Mean (SEM) 0.38 (0.07) 4.11 (0.95) 0.89 (0.19) 1.98 (0.68) 4.01 (1.03) 
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Appendix G 
pAtm 
Results of pAtm as densitometric protein results in Western blot (n = 3) as fold change and integrated 
signal intensity normalised to the housekeeper α-actin in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
Protein (fold change relative to untreated control) 
  1.92  2.04 2.87 
  15.35  3.50 2.17 
  2.34  1.59 2.90 
Mean (SEM)  6.54 (4.41)  2.38 (0.58) 2.65 (0.24) 
Protein (integrated signal intensity) 
 1.12 2.15 0.93 1.90 2.67 
 0.26 3.99 0.30 1.05 0.65 
 1.32 3.09 1.18 1.88 3.42 
Mean (SEM) 0.90 (0.33) 3.08 (0.53) 0.80 (0.26) 1.61 (0.28) 2.25 (0.83) 
 
  
Appendix 96 
Appendix H 
MDM2 
Results of MDM2 in real-time RT-PCR (n = 3) as fold change relative to untreated control calculated 
using the ΔΔCp method and absolute data calculated using the ΔCp method and densitometric 
protein results in Western blot (n = 7) as fold change and integrated signal intensity; normalised to 
the housekeeper GAPDH in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  4.785  1.520 3.125 
  4.719  1.535 1.973 
  3.998  1.429 2.596 
Mean (SEM)  4.501 (0.252)  1.495 (0.033) 2.565 (0.333) 
mRNA (absolute data) 
 0.003 0.020 0.007 0.011 0.027 
 0.004 0.025 0.010 0.017 0.023 
 0.003 0.018 0.005 0.007 0.015 
Mean (SEM) 0.003 (0.0002) 0.021 (0.002) 0.007 (0.002) 0.012 (0.003) 0.022 (0.003) 
Protein (fold change relative to untreated control) 
  2.87  0.94 1.27 
  0.86  0.91 0.83 
  1.76  1.11 1.77 
  0.87  0.95 0.91 
  1.96  1.50 1.16 
  1.01  1.08 0.61 
  0.97  0.65 0.56 
Mean (SEM)  1.47 (0.29)  1.02 (0.10) 1.01 (0.16) 
Protein (integrated signal intensity) 
 0.21 0.18 0.23 0.21 0.19 
 0.15 0.43 0.33 0.31 0.42 
 1.47 2.58 2.30 2.56 4.07 
 0.46 0.40 0.81 0.77 0.74 
 0.71 1.39 0.96 1.44 1.11 
 2.32 2.35 3.85 4.14 2.33 
Mean (SEM) 1.14 (0.39) 1.42 (0.41) 2.21 (0.93) 2.00 (0.68) 1.82 (0.62) 
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Appendix I 
p21 
Results of p21 in real-time RT-PCR (n = 3) as fold change relative to untreated control calculated 
using the  ΔΔCp method and absolute data calculated using the ΔCp method and densitometric 
protein results in Western blot (n = 3) as fold change and integrated signal intensity; normalised to 
the housekeeper α-actin in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  9.496  2.534 8.619 
  6.239  2.611 5.199 
  6.713  1.921 5.206 
Mean (SEM)  7.483 (1.016)  2.355 (0.218) 6.341 (1.139) 
mRNA (absolute data) 
 0.013 0.162 0.025 0.070 0.271 
 0.023 0.174 0.033 0.096 0.205 
 0.013 0.107 0.018 0.038 0.115 
Mean (SEM) 0.016 (0.003) 0.148 (0.021) 0.026 (0.004) 0.068 (0.017) 0.197 (0.045) 
Protein (fold change relative to untreated control) 
  1.73  1.16 1.76 
  1.56  0.89 1.04 
  1.29  1.18 1.15 
Mean (SEM)  1.53 (0.13)  1.08 (0.09) 1.32 (0.22) 
Protein (integrated signal intensity) 
 1.84 3.19 1.59 1.84 2.80 
 0.95 1.48 1.49 1.33 1.55 
 1.32 1.70 1.43 1.69 1.65 
Mean (SEM) 1.37 (0.26) 2.12 (0.54) 1.50 (0.05) 1.62 (0.15) 2.00 (0.40) 
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SIP 
Results of p21 in real-time RT-PCR (n = 3) as fold change relative to untreated control using the  ΔΔCp 
method and absolute data calculated using the ΔCp method and densitometric protein results in 
Western blot (n = 5) as fold change and integrated signal intensity; normalised to the housekeeper 
GAPDH in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  7.836  1.569 1.811 
  5.633  1.229 1.171 
  3.601  1.495 2.695 
Mean (SEM)  5.690 (1.223)  1.431 (0.103) 1.892 (0.442) 
mRNA (absolute data) 
 2.6∙10-4 2.2∙10-3 7.8∙10-4 1.3∙10-3 1.5∙10-3 
 5.0∙10-4 3.0∙10-3 1.2∙10-3 1.5∙10-3 1.4∙10-3 
 3.8∙10-4 1.4∙10-3 6.0∙10-4 9.1∙10-4 1.7∙10-3 
Mean (SEM) 3.8∙10-4 
(7.0∙10-5) 
2.2∙10-3  
(4.6∙10-4) 
8.5∙10-4  
(1.6∙10-4) 
1.2∙10-3  
(1.5∙10-4) 
1.5∙10-3  
(9.3∙10-5) 
Protein (fold change relative to untreated control) 
  1.40  0.87 0.84 
  1.26  1.22 1.31 
  0.58  1.31 1.35 
  0.74  0.63 0.73 
  0.84  0.73 0.75 
Mean (SEM)  0.96 (0.16)  0.95 (0.13) 0.99 (0.14) 
Protein (integrated signal intensity) 
 0.47 0.65 1.50 1.30 1.25 
 0.40 0.51 1.12 1.36 1.47 
 0.59 0.34 0.90 1.18 1.22 
 0.60 0.45 1.79 1.13 1.30 
 0.47 0.39 0.98 0.72 0.73 
Mean (SEM) 0.51 (0.04) 0.47 (0.05) 1.26 (0.17) 1.14 (0.11) 1.20 (0.12) 
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Appendix K 
XPC 
Results of XPC in real-time RT-PCR (n = 3) as fold change relative to untreated control using the  ΔΔCp 
method and absolute data calculated using the ΔCp method and densitometric protein results in 
Western blot (n = 5) as fold change and integrated signal intensity; normalised to the housekeeper 
GAPDH in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  3.385  1.572 1.586 
  2.783  1.005 0.849 
  2.505  1.414 2.210 
Mean (SEM)  2.891 (0.260)  1.331 (0.167) 1.548 (0.393) 
mRNA (absolute data) 
 0.008 0.032 0.021 0.034 0.034 
 0.009 0.030 0.023 0.023 0.019 
 0.007 0.020 0.011 0.016 0.026 
Mean (SEM) 0.008 (0.001) 0.027 (0.004) 0.018 (0.004) 0.024 (0.005) 0.026 (0.004) 
Protein (fold change relative to untreated control) 
  1.38  0.80 0.97 
  1.77  1.39 1.71 
  1.33  1.25 1.25 
  1.47  0.68 1.32 
  1.09  1.56 1.66 
Mean (SEM)  1.41 (0.11)  1.13 (0.17) 1.38 (0.14) 
Protein (integrated signal intensity) 
 0.93 1.28 1.21 0.97 1.18 
 0.83 1.48 0.96 1.33 1.64 
 0.93 1.23 1.07 1.34 1.34 
 0.72 1.06 1.15 0.78 1.52 
 1.20 1.31 1.33 2.08 2.22 
Mean (SEM) 0.92 (0.08) 1.27 (0.07) 1.15 (0.06) 1.30 (0.22) 1.58 (0.18) 
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Appendix L 
GADD45a 
Results of GADD45a in real-time RT-PCR (n = 3) as fold change relative to untreated control using the  
ΔΔCp method and absolute data calculated using the ΔCp method and densitometric protein results 
in Western blot (n = 4) as fold change and integrated signal intensity; normalised to the housekeeper 
GAPDH in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  5.497  1.719 2.727 
  3.014  1.667 1.770 
  3.036  1.306 2.088 
Mean (SEM)  3.849 (0.824)  1.564 (0.130) 2.195 (0.282) 
mRNA (absolute data) 
 0.005 0.034 0.018 0.034 0.058 
 0.010 0.037 0.024 0.043 0.046 
 0.007 0.027 0.012 0.017 0.029 
Mean (SEM) 0.007 (0.002) 0.033 (0.003) 0.018 (0.003) 0.031 (0.008) 0.044 (0.008) 
Protein (fold change relative to untreated control) 
  0.67  0.95 0.81 
  1.30  0.91 0.89 
  0.76  1.03 0.90 
  0.75  1.05 0.73 
Mean (SEM)  0.87 (0.15)  0.98 (0.03) 0.83 (0.04) 
Protein (integrated signal intensity) 
 1.15 0.77 1.51 1.44 1.22 
 0.81 1.05 0.86 0.77 0.76 
 0.78 0.59 0.87 0.89 0.78 
 0.94 0.70 1.22 1.28 0.88 
Mean (SEM) 0.92 (0.09) 0.78 (0.10) 1.12 (0.16) 1.10 (0.16) 0.91 (0.11) 
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Appendix M 
Validation of the micro array data 
Fold change of the 10 significantly up- or down-regulated genes on the microarray.  
Cell line A549 A549rCDDP2000 
Treatment concentration 11 µM 11 µM 34 µM 
Gene mRNA (fold change relative to untreated control on microarray) 
HRas n.s. n.s. 2.34 
MDM2 5.22 2.15 3.25 
p21 8.60 2.65 6.82 
JNK3 n.s. -4.77 -3.80 
Wnt4 -2.62 n.s. 6.08 
CCL2 5.76 n.s. 5.33 
SLC9A9 n.s. -7.43 -36.57 
DOK1 n.s. n.s. n.s. 
p38 n.s. n.s. n.s. 
DNER -4.83 -.206 -5.39 
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Appendix N 
HRas 
Results of HRas in real-time RT-PCR (n = 3) as fold change relative to untreated control using the  
ΔΔCp method and absolute data calculated using the ΔCp method and densitometric protein results 
in Western blot (n = 6) as fold change and integrated signal intensity; normalised to the housekeeper 
GAPDH in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  2.230  1.410 2.470 
  1.430  1.900 7.570 
  1.640  0.810 1.360 
Mean (SEM)  1.767 (0.240)  1.373 (0.315) 3.800 (1.912) 
mRNA (absolute data) 
 0.018 0.045 0.014 0.023 0.046 
 0.018 0.028 0.013 0.028 0.131 
 0.016 0.028 0.023 0.020 0.0380 
Mean (SEM) 0.007 (0.002) 0.033 (0.003) 0.018 (0.003) 0.031 (0.008) 0.044 (0.008) 
Protein (fold change relative to untreated control) 
  1.23  0.93 0.73 
  1.58  0.70 0.75 
  1.19  0.71 0.66 
  0.76  0.87 0.90 
  1.51  0.42 0.51 
  0.76  0.84 0.52 
Mean (SEM)  1.17 (0.14)  0.75 (0.08) 0.68 (0.06) 
Protein (integrated signal intensity) 
 0.13 0.16 0.15 0.14 0.11 
 0.12 0.19 0.20 0.14 0.15 
 0.77 0.92 1.21 0.86 0.80 
 1.19 0.91 1.69 1.47 1.52 
 0.80 1.21 2.24 0.93 1.15 
 1.15 0.87 2.46 2.07 1.27 
Mean (SEM) 0.69 (0.19) 0.71 (0.18) 1.33 (0.40) 0.94 (0.31) 0.83 (0.24) 
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Appendix O 
JNK3 
Results of JNK3 in real-time RT-PCR (n = 3) as fold change relative to untreated control using the  
ΔΔCp method and absolute data calculated using the ΔCp method and densitometric protein results 
in Western blot (n = 9) as fold change and integrated signal intensity; normalised to the housekeeper 
GAPDH in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  0.160  0.240 0.020 
  0.110  0.160 0.050 
  0.030  0.230 0.040 
Mean (SEM)  0.100 (0.038)  0.210 (0.025) 0.037 (0.009) 
mRNA (absolute data) 
 1.0∙10-5 1.9∙10-6 3.3∙10-4 9.1∙10-5 1.1∙10-5 
 1.7∙10-5 2.2∙10-6 1.3∙10-4 2.4∙10-5 7.5∙10-6 
 3.1∙10-5 1.2∙10-6 4.9∙10-4 1.3∙10-4 2.4∙10-5 
Mean (SEM) 1.9∙10-5  
(6.1∙10-6) 
1.7∙10-6  
(2.9∙10-7) 
3.1∙10-4  
(1.0∙10-4) 
8.1∙10-5  
(3.0∙10-5) 
1.4∙10-5  
(5.1∙10-6) 
Protein (fold change relative to untreated control) 
  0.67  0.76 0.73 
  0.60  1.54 0.58 
  0.65  0.86 0.48 
  0.76  0.66 0.72 
  0.80  1.47 0.72 
  1.34  0.63 0.34 
  1.29  1.45 0.72 
  1.64  1.00 0.67 
  1.50  1.61 1.22 
Mean (SEM)  1.17 (0.14)  0.75 (0.08) 0.68 (0.06) 
Protein (integrated signal intensity) 
 0.54 0.36 0.37 0.28 0.27 
 0.63 0.38 0.59 0.91 0.34 
 0.20 0.13 0.21 0.18 0.10 
 0.21 0.16 0.32 0.21 0.23 
 0.64 0.51 0.53 0.78 0.38 
 0.18 0.24 0.32 0.20 0.11 
 0.28 0.36 0.29 0.42 0.21 
 0.11 0.18 0.15 0.15 0.10 
 0.18 0.27 0.23 0.37 0.28 
Mean (SEM) 0.33 (0.07) 0.29 (0.04) 0.33 (0.05) 0.39 (0.09) 0.22 (0.03) 
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Appendix P 
p38 
Results of p38 in real-time RT-PCR (n = 3) as fold change relative to untreated control using the  ΔΔCp 
method and absolute data calculated using the ΔCp method and densitometric protein results in 
Western blot (n = 6) as fold change and integrated signal intensity; normalised to the housekeeper 
GAPDH in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  1.310  0.800 0.990 
  1.460  0.940 1.880 
  1.380  0.520 0.600 
Mean (SEM)  1.383 (0.043)  0.753 (0.124) 1.157 (0.379) 
mRNA (absolute data) 
 2.4∙10-3 3.3∙10-3 6.9∙10-3 5.7∙10-3 7.7∙10-3 
 1.8∙10-3 2.8∙10-3 4.1∙10-3 4.0∙10-3 8.2∙10-3 
 2.3∙10-3 3.2∙10-3 9.1∙10-3 4.8∙10-3 5.8∙10-3 
Mean (SEM) 2.2∙10-3  
(1.6∙10-5) 
3.1∙10-3 
(1.3∙10-5) 
6.7∙10-3  
(1.4∙10-3) 
4.8∙10-3  
(5.0∙10-5) 
7.2∙10-3  
(7.3∙10-4) 
Protein (fold change relative to untreated control) 
  0.93  1.10 1.08 
  0.97  1.39 1.27 
  0.90  1.06 0.81 
  1.39  0.93 0.83 
  0.82  1.26 1.23 
  0.68  0.81 0.83 
Mean (SEM)  0.95 (0.10)  1.09 (0.09) 1.01 (0.09) 
Protein (integrated signal intensity) 
 0.82 0.73 0.78 0.83 0.64 
 0.91 0.75 0.42 0.53 0.52 
 1.09 1.52 0.97 0.90 0.80 
 1.13 1.10 0.92 1.28 1.16 
 1.70 1.16 1.22 0.98 1.01 
 1.22 1.14 0.91 1.00 0.99 
Mean (SEM) 1.15 (0.13) 1.07 (0.12) 0.87 (0.11) 0.92 (0.10) 0.85 (0.10) 
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Appendix Q 
CCL2 
Results of CCL2 in real-time RT-PCR (n = 3) as fold change relative to untreated control using the  
ΔΔCp method and absolute data calculated using the ΔCp method and densitometric protein results 
in Western blot (n = 4) as fold change and integrated signal intensity; normalised to the housekeeper 
GAPDH in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  7.630  2.410 14.220 
  4.150  4.320 29.230 
  4.510  1.050 2.320 
Mean (SEM)  5.430 (1.105)  2.593 (0.948) 15.260 (7.786) 
mRNA (absolute data) 
 8.5∙10-5 1.2∙10-3 1.2∙10-4 3.0∙10-4 3.1∙10-3 
 2.6∙10-4 1.6∙10-2 2.8∙10-4 1.3∙10-3 1.5∙10-2 
 2.3∙10-4 1.3∙10-3 1.9∙10-4 2.2∙10-3 6.1∙10-4 
Mean (SEM) 1.9∙10-4  
(5.5∙10-5) 
6.2∙10-4  
(4.9∙10-4) 
1.9∙10-4  
(4.5∙10-5) 
6.1∙10-4  
(3.5∙10-4) 
6.1∙10-3  
(4.4∙10-3) 
Protein (fold change relative to untreated control) 
  1.00  0.90 1.50 
  0.80  0.85 1.15 
  0.96  0.96 1.12 
  0.88  1.20 1.05 
Mean (SEM)  0.91 (0.05)  0.98 (0.08) 1.21 (0.10) 
Protein (integrated signal intensity) 
 0.11 0.11 0.10 0.09 0.15 
 0.10 0.08 0.13 0.11 0.15 
 0.27 0.26 0.26 0.25 0.29 
 0.24 0.21 0.20 0.24 0.21 
Mean (SEM) 0.18 (0.04) 0.17 (0.04) 0.17 (0.36) 0.17 (0.04) 0.20 (0.03) 
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Appendix R 
DOK1 
Results of CCL2 in real-time RT-PCR (n = 3) as fold change relative to untreated control using the  
ΔΔCp method and absolute data calculated using the ΔCp method and densitometric protein results 
in Western blot (n ≤ 8) as fold change and integrated signal intensity; normalised to the housekeeper 
α-actin in A549 and A549rCDDP2000 cells. 
Cell line A549 A549rCDDP2000 
Treatment 
concentration 
control 11 µM control 11 µM 34 µM 
mRNA (fold change relative to untreated control) 
  0.670  1.780 1.810 
  3.050  3.810 2.080 
  1.370  1.090 1.430 
Mean (SEM)  1.697 (0.706)  2.227 (0.816) 1.773 (0.189) 
mRNA (absolute data) 
 2.0∙10-4 1.4∙10-4 9.9∙10-5 1.7∙10-4 1.7∙10-4 
 2.4∙10-4 6.0∙10-4 2.1∙10-4 7.3∙10-4 4.1∙10-4 
 4.0∙10-4 5.2∙10-4 3.0∙10-4 3.4∙10-4 4.4∙10-4 
Mean (SEM) 2.7∙10-4  
(6.1∙10-5) 
4.2∙10-4  
(1.4∙10-4) 
2.0∙10-4  
(5.8∙10-5) 
4.1∙10-4  
(1.6∙10-4) 
3.4∙10-4  
(8.4∙10-5) 
Protein (fold change relative to untreated control) 
  1.28  1.37 2.06 
  0.70  1.06 1.12 
  1.02  1.16 1.78 
  2.00  1.17 1.07 
  0.55  1.40 0.81 
  1.19  0.61 0.91 
    1.01 0.41 
    0.63 0.93 
Mean (SEM)  1.12 (0.21)  1.05 (0.11) 1.14 (0.19) 
Protein (integrated signal intensity) 
 0.60 0.77 1.13 1.55 2.33 
 1.20 0.84 1.40 1.48 1.57 
 0.63 0.64 2.66 3.09 4.74 
 0.07 0.14 1.35 1.58 1.44 
 0.26 1.71 1.20 1.68 0.97 
 0.31 0.17 4.63 2.81 4.23 
 0.21 0.25 0.99 1.00 0.41 
   0.70 0.44 0.65 
Mean (SEM) 0.47 (0.14) 0.65 (0.21) 1.76 (0.46) 1.70 (0.31) 2.04 (0.57) 
 
 
